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Abstract: 
Back ground: Glaucoma is the second leading cause for blindness worldwide (Quigley ,et al, 
2006). A significant contributing factor to this problem is low compliance with anti-glaucoma 
treatment. Ocular hypotensive medications are used by 86% of patients with glaucoma and 
are the most common treatment for glaucoma. (Friedman, et al, 2005) Although the correct 
diagnosis and appropriate treatment is a critical component in the management of this 
disease, compliance is equally importance. Patients with glaucoma most often require 
lifelong treatment and follow-up care to preserve vision. Compliance is reported worldwide 
to vary from as low as 5% to as high as 80%. (Olthoff, et al,2005) However, limited 
information is available on this issue in Middle East. In Palestine, there have been no study in 
this regard, to date.  
Aim: The aim of this study was to assess the level of compliance, and the factors affecting 
compliance to topical anti-glaucoma medication, among Palestinians with glaucoma, who 
attend SJEHG at  (Jerusalem, Hebron, and Anabta). 
Method: This study used a quantitative, descriptive, cross-sectional survey design within 
SJEHG, on 320 glaucoma patients. The psychometrics of the Glaucoma Treatment 
Compliance Assessment Tool (GTCAT), was used to assess adherence with glaucoma 
therapy. This questionnaire included items related to the six 'Health Belief Model' constructs, 
as well as other relevant information, such as age, medical history, gender, income, education 
levels, and type of insurance coverage. Most questions included a 5-interval Likert scale 
response with anchoring definitions (eg, 1=absolutely disagree, 5=absolutely agree).  
The questionnaire was filled out during face-to-face interviews between trained neutral 
interviewers and the patients. Frequencies and descriptive analysis, ANOVA test,  chi-square 
test, regression test were applied. 
 
Results: The overall noncompliance level was 71.6%. Noncompliance was found to be 
higher in males than females (74%) to (69%) respectively. Noncompliance level was higher 
in those above fifty years. Divorced glaucoma patients had the highest noncompliance level 
(94%). Retired and unemployed had a noncompliance level (81%) and (79%) respectively. 
Noncompliance level was high in glaucoma patients who were considered blind.  
 
IV 
 
Compliance was found to be related to the level of education, with the highest noncompliance 
level was in illiterate (76%). Participants generally had a moderate level of knowledge about 
their disease, which together with self efficacy affected compliance positively. 
 
Treatment barriers affected compliance negatively. The factors that had the most impact on 
compliance were, primarily: was the availability of glaucoma drops with patients at the 
prescribed the time, secondly: the side effect of glaucoma drops, thirdly: forgetfulness.  
Despite the majority of Glaucoma patients having insurance they were noncompliant, because  
their insurance didn‘t cover the cost of follow up and treatment.  
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Glaucoma, Compliance, Adherence, Glaucoma Medications (Topical anti-glaucoma 
medication)
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Chapter One 
 
Introduction: 
This chapter aims to provide the context and structural outline of the thesis. An 
overall rationale for study, is provided together with an overview of the setting of the 
study. In addition, this chapter introduces the theoretical and ethical basis of the study. 
It includes research problem, research justifications, aim and objectives of the research, 
research questions, study limitations, definitions of the key concepts, and description of 
study setting . 
Glaucoma is a preventable cause of blindness, if timely effective and successful 
treatment is provided. Patient adherence to the medication is a constant challenge that is 
now recognized as an essential component to treatment and one of the most important 
factors in controlling high intra ocular pressure (IOP), preventing and reducing chance 
of vision loss and blindness. (Robin et al., 2004)  
This quantitative, descriptive, study focuses on identifying and explaining factors 
associated with compliance to topical anti-glaucoma treatment among diagnosed 
glaucoma patients attending St. John Eye Hospital Group (SJEHG) in three cities. The 
main hospital located in middle of Palestine, Hebron branch which covers  the southern 
area and Anabta branch which covers northern area.  
 
1.1: Background  
Glaucoma is the second leading cause for blindness worldwide (Quigley, et al, 2006). 
Glaucoma with both its entities, open angle glaucoma (OAG) and angle closure 
glaucoma (ACG), affected about 60.5 million people worldwide, of whom 4.5 million 
are estimated to become legally blind 2010, this number was estimated to increase to 
79.6 million by 2020 (Quigley et al., 2006).  
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According to Quigley et al., (2006) the prevalence of primary open angle glaucoma 
(POAG) is estimated to be between 1.1% and 3% in Western populations over the age 
of 40 years  
The estimated number of POAG patients in Israel is 60,000 (Masoud et al., 2013).  
Ocular hypotensive medications are used by 86% of patients with glaucoma and are the 
most common treatment for glaucoma (Friedman et al., 2005). According to Kass et al., 
(2002) medications are very effective in reducing the development or worsening of 
glaucoma by at least 60%, compliance to topical anti-glaucoma medication has always 
been a major problem. 
 In Israel glaucoma was documented to be the third cause of blindness, accounting for 
nearly one-eighth of the cases (Avisar et al., 2006). 
Few regional studies have defined glaucoma as the leading cause of blindness at a 
prevalence rate of 2–9% in Egypt, 1.73% in Qatar, and 4.75% in Oman (Abu Hussein et 
al., 2015), in Palestine no study related this topic. Glaucoma had also been found to 
contribute to legal blindness at a rate of 8% in a study done at Cairo University 2014, 
12.1% at  Mansoura University 2002. 
Despite significant progress in the diagnosis and treatment of glaucoma, a high 
percentage of patients still losing their sight. One pertinent contributing factor to this 
problem is low compliance with anti-glaucoma treatment (Lee et al., 2000).   
In the literature, compliance is reported to vary from as low as 5% to as high as 80% 
(Olthoff et al., 2005). However, limited information is available on this issue in the 
Middle East. In Palestine, there have been no study in this regard, to date.  
The management of primary glaucoma is surrounded by an appreciable number of 
problems that do not arise in the treatment of any other disorder in ophthalmology. 
Firstly, because of the painless and gradual nature of the visual deterioration, late 
presentation to the hospital is common (Parikh et al., 2008).  
 
Adherence with glaucoma medications is a key component of a successful glaucoma 
treatment program. Everett, the former US Surgeon General, famously remarked, 
―Drugs don‘t work in patients who don‘t take them‖ (Everett, 2009, pp:184).   
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Adherence to ocular hypotensive medications is a critical part of secondary prevention 
of visual impairment from glaucoma. Ocular hypotensive medications are used by 86% 
of patients with glaucoma and are the most common treatment for glaucoma (Friedman 
et al., 2005).
   
Glaucoma patients require long-term treatment over an average of 15 years (Broman, et 
al, 2008).
 
Finally, medications are very effective in reducing the development or 
worsening of glaucoma by at least 60% ( Kass et al., 2002). 
 
 
1.2: Organizations that provide ophthalmic screening and follow up 
for glaucoma patients: 
SJEHG in its four location: Jerusalem, Hebron, Anabta, and Gaza. The Ministry of 
Health (MOH) eye clinics in the governmental hospitals: Hebron, Ramallah, Nablus, 
and Bethlehem, these provide basic medical management and treatment of glaucoma, 
SJEHG has the only glaucoma specialist in Palestine, who is able to provide a 
comprehensive glaucoma service in Jerusalem, with monthly visits to Hebron and 
Anabta.  
In Palestine we have around nine private ophthalmic centers, beside several private 
ophthalmic clinics,  which offer follow up for stable glaucoma patients.  Palestine has  
105 registered ophthalmic doctors, the ratio of ophthalmic doctor to population is 
around 1:50000 which considered good, compared to our neighboring countries like 
Jordan (Palestinian Ophthalmic Society, 2017). 
It‘s important to note that there are three main tracks of health insurance in the 
Occupied Palestinian Territories: government insurance, which encompasses (65%) of 
the residents and is affordable but with partial coverage of health needs, the United 
Nations Relief and Work Agency insurance, which is only for the refugee population 
(37%), and private insurance, which covers just (2%), and the remaining (18%) of the 
population is uninsured (MOH, 2012).  
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1.2.1: General barriers toward compliance with topical anti-glaucoma treatment 
and screening: 
In general, barriers and factors affecting glaucoma patients‘ compliance to topical 
treatments in SJEHG could include socioeconomic issues, such as the cost involved in 
seeking follow up services in addition to high cost of medication, which  affect their 
compliance level with anti-glaucoma treatment based on instability of economic and 
political situation in our country due to occupation and unexpected future events 
(political instability and conflict related occupation). 
Due to the influence of various, social, and economical factors on topical treatments, 
glaucoma patients are averse to comply with treatments at the early stages when 
treatment is most expected to be successful to save vision (Kass et al., 2002). 
Knowledge and awareness about the risks of glaucoma and the benefits of topical 
treatments may constitute barriers to the access and utilization of glaucoma topical 
treatments based on literature review (Robin et al., 2004). 
The factors can be classified into four groups, to facilitate explanation and 
understanding. These groups are patients related factors, glaucoma related factors, 
treatment related factors,  and health care provider related factors (Striker et al., 2010). 
 I believe it is very important to understand factors that affect compliance, and the 
findings of my study will be useful in order to develop interventions and program to 
address specific remaining barriers to improve compliance among Palestinian glaucoma 
patients.  
 
Having one glaucoma specialist results in patients having to wait long to see a glaucoma 
specialist. It also  restricts patients choice and may create a barrier to optimal patient 
physician relationships, which could affect their compliance level. 
The non-availability of glaucoma specialist to follow up glaucoma patient and to order 
relevant tests like visual field (VF), and central corneal thickness (CCT), Optical 
Coherence Tomography (OCT) of the optic nerve, and the lack of these machines in 
most clinics and centers outside SJEHG were considered barriers for glaucoma patients. 
These barriers leave glaucoma patients with just one choice, to visit SJEHG. This  
entails traveling long distances, the cost of transportation and time spent combined with 
medication costs may prevent glaucoma patients from accessing this service, resulting 
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in noncompliance to regular follow up and treatment, notwithstanding  the difficulties 
they face when passing through check points of Israel occupation. All these factors  may 
also lead to a disparity in compliance, between patients living in the main city and those 
in the rural areas.  
 
1.3: Study Problem             
Patients are more likely to be adherent to their medication if they understand the disease 
and the rationale for treatment and if their treatment regimen is simplified (Nordstrom 
 et al., 2005). Additionally, using eye drops has its own set of challenges that must be 
recognized and addressed at the clinical level. The numerous socioeconomic factors  
associated with poor adherence, must be addressed, at a national level. Maximizing 
patient adherence to medication has the potential to prevent unnecessary vision loss, 
reduce the number of surgical interventions required to control glaucoma, and save the 
overall healthcare system money in the long run. Results of a study published in the 
January 2014 issue of Ophthalmology shows that the risk of blindness related to 
glaucoma 20 years after diagnosis has decreased by 50% due to early intervention and 
consistent treatment (Malihi et al., 2014).  
In Palestine there is still a gap in consistent treatment resulting in our glaucoma patients 
facing blindness. The prevalence of bilateral blindness in Palestine  (Visual Acuity 
(VA) <3/60 in the better eye with available correction) was 3.4%  as reported by 
Chiang, et al (2010) study, which can be prevented or significantly reduced by working 
on the factors affecting compliance with topical by working on factors affecting 
compliance with topical anti-glaucoma treatment. Including government, and service 
providing organizations. Adherence to ophthalmic medications has a unique set of 
challenges compared to oral medications. Screening for raise Intraocular Pressure (IOP) 
is  effective in helping the physicians in early detection and treatment of glaucoma.  
 
Compliance to topical anti-glaucoma treatments can also reduce the total expenditure to 
cover treatment and medications cost for glaucoma patients, in long run term. 
Ophthalmologists may mistake noncompliance for ineffectiveness of a given anti-
glaucoma medication and prescribe more medications or shift to surgery, aggravating 
the problem with additional costs and risks (Buskirk, 1996). 
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In this study I researched the factors representing as a barriers that make glaucoma 
patients noncompliance with glaucoma topical treatment, including personal related 
factors, treatment related factors, glaucoma related factors, and health provider related 
factors.  
The results of this research gave us indicators as to whether they directly affected some 
personally, socially, or economically and health system strategy on improving 
compliance to topical anti-glaucoma treatments in SJEHG.  
 
1.4: Study justification: 
Patients with glaucoma most often require lifelong treatment and follow-up care, to 
preserve vision. The current standards for glaucoma treatment range from topical 
medications and laser procedures, to incisional surgery. Glaucoma is a preventable 
cause of blindness, however, numerous studies, in both developed and less developed 
countries, have demonstrated that access to eye care resources and adherence to 
treatment are still the major obstacles (Robin et al., 2004). 
Once the diagnosis of glaucoma has been established, effective treatment is paramount. 
Treatment involves both rationale therapeutic interventions and patient adherence to the 
intervention. The therapeutic benefit from medication is maximized when administered 
correctly. 
There is no national program for glaucoma in Palestine, Some attempts to counteract 
this have been undertaken by SJEHG and its outreach clinic, by providing screening, 
diagnostic and therapeutic services for patients with, or at risk of, developing glaucoma. 
Besides, patient and family health education on the risks of this disease. SJEHG also 
continually seek funds to help provide patients with their glaucoma medication, free or 
at a greatly subsidized fee.  From the results of this study, I hope to highlight the 
barriers to compliancy and help strategize a plan at a local and even national level to 
combat these, improving the patient‘s quality of life and reducing the negative 
socioeconomic impact, to the patient, their family and eventually nationally. 
Through my research into literature on this topic, I observed there were no publications 
on compliance among Palestinians on medically treated glaucoma. 
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My research centered on identifying the factors that affect compliance with topical anti-
glaucoma treatments in patients attending SJEHG. It is very important to determine 
what causes glaucoma patients‘ noncompliance, and the results of the research will be 
put on the agenda of the strategic solutions to improve the health status of glaucoma 
patients attending the SJEHG.  
The resulting data will also be used to educate and encourage patients to be compliant, 
reducing barriers when possible. This will eventually lead to reducing the incidence of 
unnecessary visual loss, and the need for surgical intervention. In the long term, leading 
to efficient utilization of resources and improved quality of life for these patients. 
Adherence to ophthalmic medications has a unique set of challenge 
1.5: Research Objectives: 
      1.5.1: Aim & Objectives of the study 
This study aims to assess the factors affecting compliance to topical anti-glaucoma 
treatments among Palestinian glaucoma patients who attend SJEHG at (Jerusalem, 
Hebron, and Anabta). 
 
1.5.2: General Objectives 
 To assess the compliance level of glaucoma patients who attend SJEHG clinic at 
(Jerusalem, Hebron, and Anabta) to their topical anti-glaucoma treatment.  
 To examine the relation between: 
   -   Personal characteristics of the glaucoma patients on compliance level 
   -   Socioeconomic status on their compliance level 
   - Health care providers related factors on patient‘s compliance level to topical anti-
glaucoma treatments. 
 
 To highlight the barriers, if any, so that recommendations can be incorporated into the 
strategic plans of interested organizations (ophthalmic hospital and clinic),  and policy 
makers to overcome these barriers, where possible,  for this  specific population group 
(glaucoma patients), enhancing their level of compliance. 
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1.5.3: Specific Objectives 
1. To identify the effect of age & gender characteristics on compliance to medication. 
2. To determine the effect of patient‘s formal education level on compliance to anti-
glaucoma medication. 
3. To examine the relation between how much basic knowledge the patient has related 
to their disease and compliance to anti-glaucoma medication. 
4. To examine the effect of number of eye drops used, and frequency of drops use on 
compliance to anti-glaucoma medication. 
5.  To identify the effect of having medical insurance on the patient‘s compliance to 
anti-glaucoma medications.   
6. To identify the effect of  dropper difficulties, physical inability, and side effects of 
medication on compliance to anti-glaucoma medications.   
1.5.4: Research Questions: 
1-What are the factors affecting glaucoma patient‘s compliance? 
2-What is the most important factor affecting glaucoma patient‘s compliance? 
3-What is the effect of the ophthalmic physician and nurses (health provider) related to 
glaucoma patient compliance? 
 
1.6: Study Hypotheses: 
The study question was built on the following hypotheses: 
 
 There is a significant difference at level of significant α ≤ 0. 05 in the degree of 
knowledge level and demographic variables (age, address, marital status, educational 
level, occupation, income, health insurance).  
 There is significant correlation at level of significant α  ≤ 0. 05 in the degree of 
compliance with the dropper difficulties, physical inability, and side effects of 
medication.  
 There is significant differences at level of significant α  ≤ 0. 05 in the degree of 
compliance to anti-glaucoma medication with respect to medication numbers and 
frequency of drops.  
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 There is a significant difference at level of significant α ≤ 0. 05 in the degree of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to having medical insurance. 
 There is a significant difference at level of significant α ≤ 0. 05 in the degree of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to age and gender. 
 There is a significant difference at level of significant α ≤ 0. 05 in the degree of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to address. 
 There is a significant difference at level of significant α ≤ 0. 05 in the degree of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to marital status. 
 There is a significant difference at level of significant α ≤ 0. 05 in the degree of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to educational level. 
 There is a significant difference at level of significant α ≤ 0. 05 in the degree of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to their vision. 
 
1.7: Ethical approval and confidentiality consideration: 
This study was approved by the SJEHG ethical committee and a written official letter of 
approval was granted (Annex A). Participation was voluntary; the participants were 
informed about the purpose of the study and its significance. The participants were 
assured that their responses would be confidential, completely anonymous, and only 
used for the purposes of scientific research.  
Emphasizing, autonomy, data confidentiality and the right of glaucoma patients to 
refuse to participate in the study or withdraw any time, while still being entitled to the 
best care that SJEHG can provide, at every interview. 
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1.8: Study Limitations: 
 The study was limited to glaucoma patients attending  SJEHG clinic in Jerusalem, 
Hebron, and Anabta. Therefore, this study can't be generalized to all Palestinian 
glaucoma patients. 
  Lack of research material on Palestinian glaucoma patient (no database). 
 The study population is not specified, due to lack of registration in MOH reports. 
 Some of the patients who didn‘t attend the clinic regularly may not be included in 
the study, despite the fact that these patients are very important to the study, because 
they are not compliant with their treatment. 
 The sample is not representative of all the population, because it has been done only 
on glaucoma patients at SJEHG. 
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Chapter Two 
Literature review: 
2.1: Introduction: 
This chapter aims  to examine the literature related to compliance of glaucoma 
patients to topical anti-glaucoma treatment, In addition, a review of the research-based 
literature pertaining to the barriers affecting the compliance of the glaucoma patient and 
to determine the level of awareness and perspective of Palestinian glaucoma patients‘ 
responses to lifelong anti-glaucoma treatment. Researcher focuses on the definition of 
glaucoma, types, causes, and treatment of glaucoma. 
This literature review aims to look into the factors influencing compliance, and 
facilitates the search process, based on previous studies. These factors will be studied 
under the following four parameters: personal related factors,  treatment related factors,  
health provider related factors, and glaucoma related factors 
 
 2.1.1: Literature Search Strategy:  
 
The literature search strategy focused on the purpose of the research, that is; to explore 
the personal related factors and the effect of the socio-economic situation, and 
demographic factors on compliance to topical anti-glaucoma treatments.  
There are different kinds of resources including: books, journal articles, policies, 
directives and web sources. Overall, I found 90 sources, around 60 of which were used 
according to the key words criteria and also because they fitted the main objective of the 
study. The other sources were excluded because their goals were irrelevant or 
unsuitable.    
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All these types of resources are important in the research process, but they differ in 
many ways. It is also crucial to verify the accuracy and reliability of any data sources, 
the key search terms were: ―factors affecting glaucoma patient compliance‖.  
All Studies that have been read, including Arabic and international, related to the study, 
were well-read and the results understood and linked to the aim of the study. All studies 
were arranged by year of publication.  
 
2.2: Definition of glaucoma: 
2.2.1: What is  Glaucoma: 
 
Glaucoma  is a complicated eye diseases which results in damage to the optic nerve to  
progressive irreversible vision loss. A major risk factor is increased pressure in the eye 
(Casson et al., 2012).  
 
Glaucoma is a group of clinical disorders that are characterized by optic nerve damage 
and visual field defects. The intraocular pressure levels may exceed the tolerance of the 
affected eye. The level of intraocular pressure that causes organic change is not 
definable since it varies widely from one eye to the other and some eyes may tolerate 
for long periods a pressure that would rapidly blind another (Blondeau et al., 2007). 
 
Glaucoma can permanently damage vision in the affected eye, first by decreasing 
peripheral vision (reducing the visual field), and then potentially leading to blindness if 
left untreated. For eye pressures a value of greater than 21 mmHg is often used with 
higher pressures leading to a greater risk. However, some may have high eye pressure 
for years and never develop damage. Conversely, optic nerve damage may occur with 
normal pressure, known as normal-tension glaucoma (Rhee, and Douglas, 2013). 
 
2.2.2: Types of  Glaucoma: 
There are several types of glaucoma. The two main types are open-angle (OAG) and 
angle-closure (ACG). These are marked by an increase of intraocular pressure (IOP), or 
pressure inside the eye. 
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Open-Angle Glaucoma (OAG): 
Open-angle glaucoma, the most common form of glaucoma, accounting for at least 90% 
of all glaucoma cases: 
 Is caused by the slow clogging of the drainage canals, resulting in increased eye 
pressure.  
 Has a wide and open angle between the iris and cornea. 
 Develops slowly and is a lifelong condition. 
 Has symptoms and damage that are not noticed. 
  
 
 
―Open-angle‖ means that the angle where the iris meets the cornea is as wide and open 
as it should be. Open-angle glaucoma is also called primary or chronic glaucoma. It is 
the most common type of glaucoma, affecting about three million Americans. 
 
Angle-Closure Glaucoma (ACG): 
Angle-closure glaucoma, a less common form of glaucoma: 
 Is caused by blocked drainage canals, resulting in a sudden rise in intraocular 
pressure. 
 Has a closed or narrow angle between the iris and cornea. 
14 
 
 Develops very quickly. 
 Has symptoms and damage that are usually very noticeable. 
 Demands immediate medical attention. 
 
 
 
 
It is also called acute glaucoma or narrow-angle glaucoma. Unlike open-angle 
glaucoma, angle-closure glaucoma is a result of the angle between the iris and cornea 
closing. 
 
Normal-Tension Glaucoma (NTG): 
Also called low-tension or normal-pressure glaucoma. In normal-tension glaucoma the 
optic nerve is damaged even though the eye pressure is not very high. We still don't 
know why some people‘s optic nerves are damaged even though they have almost 
normal pressure levels. 
 
Congenital Glaucoma: 
This type of glaucoma occurs in babies when there is incorrect or incomplete 
development of the eye's drainage canals during the prenatal period. This is a rare 
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condition that may be inherited. When uncomplicated, microsurgery can often correct 
the structural defects. Other cases are treated with medication and surgery. 
 
Other Types of Glaucoma 
Variants of open-angle and angle-closure glaucoma include: 
 Secondary Glaucoma 
 Pigmentary Glaucoma 
 Pseudoexfoliative Glaucoma 
 Traumatic Glaucoma 
 Neovascular Glaucoma 
 Irido Corneal Endothelial Syndrome (ICE) 
 Uveitic Glaucoma 
 
 
2.2.3: Causes of  Glaucoma: 
 
Risk factors for glaucoma include increased pressure in the eye, a family history of the 
condition, migraines, high blood pressure, and obesity. The most common type is open-
angle glaucoma with less common types including closed-angle glaucoma and normal-
tension glaucoma. Open-angle glaucoma develops slowly over time and there is no 
pain. Side vision may begin to decrease followed by central vision resulting in blindness 
if not treated.  
 
Closed-angle glaucoma can present gradually or suddenly. The mechanism of open-
angle glaucoma is believed to be slow drainage of aqueous humor through the 
trabecular meshwork while in closed-angle glaucoma the iris blocks the trabecular 
meshwork. Diagnosis is by a dilated eye exam. Often the optic nerve shows an 
abnormal amount of cupping. It occurs more commonly among older people. Closed-
angle glaucoma is more common in women (Casson et al., 2012; Rhee, and Douglas, 
2013). 
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Glaucoma has been called the "silent thief of sight" because the loss of vision usually 
occurs slowly over a long period of time (National Eye Institution, 2014). 
Of the several causes for glaucoma, ocular hypertension (increased pressure within the 
eye) is the most important risk factor in most glaucomas, but in some populations, only 
50% of people with primary open-angle glaucoma actually have elevated ocular 
pressure (Broman et al., 2008).  
Open-angle glaucoma accounts for 90% of glaucoma cases in the United States. Closed-
angle glaucoma accounts for less than 10% of glaucoma cases in the United States, but 
as many as half of glaucoma cases in other nations (particularly Asian countries) 
(Broman et al., 2008). 
Genetics: 
Positive family history is a risk factor for glaucoma. The relative risk of having primary 
open-angle glaucoma (POAG) is increased about two- to four-fold for individuals who 
have a sibling with glaucoma (Myron et al., 2009). 
 Glaucoma, particularly primary open-angle glaucoma, is associated with mutations in 
several genes (including MYOC, ASB10, WDR36, NTF4,and TBK1 genes). 
Although most cases of glaucoma do not involve these genetic mutations. Normal-
tension glaucoma, which comprises one-third of POAG, is also associated with genetic 
mutations (including OPA1 and OPTN genes).  
Other factors can cause glaucoma, known as "secondary glaucoma", including 
prolonged use of steroids (steroid-induced glaucoma), conditions that severely restrict 
blood flow to the eye, such as severe diabetic retinopathy and central retinal vein 
occlusion (neovascular glaucoma), ocular trauma  (angle-recession glaucoma), 
and uveitis (uveitic glaucoma). 
 
2.2.4: Complication of Glaucoma: 
Vision loss from glaucoma, once it has occurred, is permanent, gradually 
progressive visual field loss, and optic nerve changes (increased cup-to-disc 
ratio on fundoscopic examination) which lead to irreversible blindness (Casson et al.,  
2012). 
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2.2.5: Treatment of Glaucoma: 
The modern goals of glaucoma management are to avoid glaucomatous damage and 
nerve damage, and preserve visual field and total quality of life for patients, with 
minimal side effects (Parikh et al., 2008). 
This requires appropriate diagnostic techniques and follow-up examinations, and 
judicious selection of treatments for the individual patient. Although intraocular 
pressure is only one of the major risk factors for glaucoma, lowering it via various 
pharmaceuticals and/or surgical techniques is currently the mainstay of glaucoma 
treatment. Intraocular pressure can be lowered with medication, usually eye drops. 
Several classes of medications are used to treat glaucoma, with several medications in 
each class. 
Each of these medicines may have local and systemic side effects. Adherence to 
medication protocol can be confusing and expensive, if side effects occur, the patient 
must be willing either to tolerate them or to communicate with the treating physician to 
improve the drug regimen. Initially, glaucoma drops may reasonably be started in either 
one or in both eyes (Leffler, and Amini, 2007).  
 
2.2.5.1: Medications used are: 
 Prostaglandin analogs, such as Latanoprost, Bimatoprost and Travoprost, increase 
uveoscleral outflow of aqueous humor. Bimatoprost also increases trabecular outflow. 
 Topical beta-adrenergic receptor antagonists, such as Timolol, Levobunolol, 
and Betaxolol, decrease aqueous humor production by the epithelium of the ciliary 
body. 
 Alpha2-adrenergic agonists, such as Brimonidine and Apraclonidine, work by a dual 
mechanism, decreasing aqueous humor production and increasing uveoscleral outflow. 
 Less-selective alpha agonists, such as epinephrine, decrease aqueous humor 
production through vasoconstriction of ciliary body blood vessels, useful only in  
 open-angle glaucoma. Epinephrine's mydriatic effect, however, renders it unsuitable 
for closed-angle glaucoma due to further narrowing of the uveoscleral outflow (i.e. 
further closure of trabecular meshwork, which is responsible for absorption of aqueous 
humor). 
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 Miotic agents (parasympathomimetics), such as pilocarpine, work by contraction of 
the ciliary muscle, opening the trabecular meshwork and allowing increased outflow of 
the aqueous humour. Echothiophate, an acetylcholinesterase inhibitor, is used in chronic 
glaucoma. 
 Carbonic anhydrase inhibitors, such as dorzolamide, brinzolamide,and acetazolamide, 
lower secretion of aqueous humor by inhibiting carbonic anhydrase in the ciliary body.            
 Both laser and conventional surgeries are performed to treat glaucoma. Surgery is the 
primary therapy for those with congenital glaucoma. Generally, these operations are a 
temporary solution, as there is not yet a cure for glaucoma. 
2.2.5.2: Side Effects of Glaucoma Medications: 
Following are some of the potential side effects of the most commonly prescribed types 
of glaucoma medications. 
-Prostaglandin Analogs: possible changes in eye color and eyelid skin, stinging, blurred 
vision, eye redness, itching, burning. 
-Beta Blockers: low blood pressure, reduced pulse rate, fatigue, shortness of breath, 
rarely reduced libido, depression. 
-Alpha Agonists: burning or stinging, fatigue, headache, drowsiness, dry mouth and 
nose, relatively higher likelihood of allergic reaction. 
-Carbonic Anhydrase Inhibitors: in eye drop form: stinging, burning, eye discomfort, in 
pill form: tingling hands and feet, fatigue, stomach upset, memory problems, frequent 
urination. 
Side Effects of glaucoma medication, of which the most common being bitter taste, 
stinging and redness. Dry eye patients who experience symptoms before glaucoma 
therapy may notice an exacerbation of symptoms once glaucoma drops are added. These 
effects, when combined with the absence of any observable benefit, may discourage 
patients from complying.  
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2.3: Glaucoma Compliance to Medical Treatment (Topical eye drops): 
Compliance attributed to many factors like age, gender, level of education, and fear of 
blindness. Other factors include poor communication with the health care provider, cost 
of eye drops, forgetfulness, and difficulty in instilling the eye drops (Friedman et al., 
2008). Compliance is a multifactorial complex behavior (Friedman et al., 2008). 
Previous study have provided insight into the factors associated with glaucoma 
adherence. Lacey and associates  showed adherence to be associated with fear of 
blindness, forgetfulness, difficulty with drop application, and age (Lacey et al., 2009).  
Friedman and associates found adherence to be associated with method of 
communication, patient education, risk of vision loss, cost, traveling, side effects, and 
demographic factors. Other researchers have shown that low health literacy is associated 
with poor adherence (Friedman et al., 2008). 
 
2.4: Determinants of Compliance: 
Glaucoma medication adherence could be measured through self-report, pharmacy refill 
reports, electronic monitoring and direct observation. To be clinically relevant, an 
‗acceptable‘ adherence level should be determined by its impact on clinical outcome 
(Olthoff et al., 2005). 
Assessing compliance in ocular treatment is difficult compared to other medical 
therapies. In other systemic medication, compliance could be assessed by blood level of 
the medication in addition to the response to treatment. Intraocular pressure (IOP) 
assessment as an indicator of compliance is associated with ―white coat syndrome‖ with 
a percentage of patients adhering to their medication regimen in the days preceding 
doctor visit and declining thereafter (Olthoff et al., 2005). 
 
The degree of compliance was evaluated in this study by using Glaucoma Treatment 
and Compliance Assessment Tool (GTCAT) compliance, which was calculated, based 
on the total degree of questionnaire multiple axis. The degree of symptoms and 
complications related to glaucoma and its medication, were investigated using the 
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(GTCAT). As were the effect of sex, age, treatment duration, knowledge about the 
glaucoma medication, number of eye drops and family support for eye drop use. 
2.5: Literature Review: 
 
Treatment adherence is a complex behaviour  that is influenced by many factors. To 
date, most glaucoma adherence studies have focused on use of medications, mainly eye 
drops (Quigley et al., 2007). 
Barriers to glaucoma treatment adherence can be divided into three categories according 
to Mantravadi et al., (2012): provider related factors, medication related factors, with  
situational/environmental factors. The factors affect compliance with treatment in 
glaucoma are based on a prospective series of interviews with patients were grouped 
into three broad categories: 
• Environmental and/or situational factors (49 %) 
• Medication regimen factors (32 %) 
• Patient-related factors (16 %) (Mantravadi et al., 2012). 
 
Adherence and Persistence: The Challenges for Glaucoma Medical Therapy. Study by 
Skalicky et al., (2013)  found that suboptimal adherence and persistence to therapy are 
major challenges for patients treated with ocular hypotensive medications. The problem 
affects 5% to 80% of glaucoma patients from all nations, ethnicities, socioeconomic 
backgrounds, and education levels. Although health care providers are generally poor at 
detecting suboptimal or poor adherence in the clinical setting. 
2.5.1: Patient  related Factors with situational/environmental factors: 
Evidence regarding the relationship between demographic factors such as race/ethnicity, 
gender, socioeconomic status, education, family history and age, and glaucoma 
treatment adherence is largely inconsistent. Ethnic disparities in adherence to glaucoma 
treatment or glaucoma awareness are often, but not always, noted (Muir et al., 2006; 
Taylor et al., 2002). and These associations between glaucoma treatment adherence with 
education and socio-economic status may be confounded which are often lower among 
African American patients (National Eye Institute, 2007).  
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Older patients may exhibit poor glaucoma treatment adherence due to difficulty reading 
prescription labels (Sleath et al., 2006). 
 Younger patients  (<55 years of age) self-reported non-adherence, had a higher risk of 
being non-adherent (Olthoff et al., 2009). 
Risk factors for poor adherence or non-adherence to topical glaucoma medication 
regimens obstacles are common in the elderly (e.g., reduced cognition, musculoskeletal 
problems, and transportation difficulties) (Tsai, 2009).  
Older age has not been shown to be a consistent risk factor for poor adherence to 
glaucoma medication regimens (Tsai, 2009). 
A study by Masoud et al., (2013), shows that poor compliance to medical therapy 
occurred in large percent of the patients, mostly those in the older age groups and those 
who had no knowledge of the nature of the disease and its treatment  
Factors associated with nonadherence included inadequate knowledge get the high 
percent (32%), underestimation of the disease severity get the second percent (25.5%), 
while the denial get the lowest percent 15.5% (Masoud et al., 2013). 
Physical challenges in self-administering drops are commonly cited barriers to 
glaucoma adherence (Kahook, 2007). 
A study by Gupta et al., (2012), showed that when the eye drop application techniques 
of 70 open- and closed-angle glaucoma patients were assessed, nine out of ten were 
unable to instill their eye drops correctly. 
A high prevalence of non-compliance, compounded by an inability to instill a drop into 
the eye due to physical impairment. About half of the patients had difficulty aiming the 
drop, and other problems including squeezing the bottle, blinking, and seeing the tip of 
the bottle, Because most of glaucoma patients are old age. The grip strength of patients 
to and force required to expel a drop from a bottle is affected by ages and diseases like 
some patients, particularly those with arthritis, could not generate enough force to 
squeeze  a bottle. These same patients also had difficulty with the other movements 
required to administer drops. Non-adherent glaucoma patients are more likely to have 
impaired visual acuity or partial vision loss (Sleath et al., 2006).  
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Data regarding gender differences in glaucoma adherence are inconsistent. General rate 
of noncompliance, for both genders, was found to be 50%. Compliance rates were 
unaffected by gender or number of prescribed drugs. Compliance was significantly 
higher in younger patients (age < 50) and in older patients (age > 80), 63% and 77%, 
respectively. Noncompliance with glaucoma treatment was found to be common among 
an Arab population in Israel, particularly between the ages of 50 and 80 (Masoud et al., 
2013). 
Females had a tendency for higher compliance than male in Egypt (Abu Hussein et al., 
2015). 
A study by Khandekar et al., (2005) reported that gender per se is not associated with 
increased noncompliance. 
The most pervasive cognitive factor influencing adherence is forgetfulness. 
Forgetfulness was the number one reported reason for non-compliance (Taylor, 2002). 
Forgetfulness, unavailability of eye drops and difficulties with holding the bottle above 
the eye when applying the eye drops were the most cited reasons for non-adherence 
(Olthoff et al., 2009). 
 Fifty percent of the patients indicated that they required more information on the 
correct administration of eye drops. There was no association between non-adherence 
and sex, level of education, type of insurance, duration of disease or family history of 
glaucoma (Olthoff et al., 2009). 
Other psychosocial factors that may influence glaucoma treatment adherence include 
beliefs and attitudes, self-efficacy, and social support. Lack of perceived benefit of 
treatment or satisfaction with treatment has been consistently associated with lower self-
reported adherence (Day et al., 2006).  
Results of several studies revealed that the top five barriers included problems with 
glaucoma patients are: 
         1) forgetfulness 
         2) side effects 
         3) cost/affordability 
         4) eye drop administration 
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         5) the eye drop schedule (Lacey et al., 2009; Stryker et al., (2010); Laura et al., 
2013; Masoud et al., 2013). 
         The most salient top five facilitators were : 
         1) fear or thoughts about the consequences of not taking eye drops 
         2) use of memory aids, cues, or strategies 
         3) maintaining a regular routine or schedule for eye drop administration 
         4) ability to afford eye drops 
         5) keeping eye drops in the same area (Lacey et al., 2009; Stryker et al., (2010); 
Laura et al., 2013; Masoud et al., 2013). 
 
A study was done in Haifa and Western Galilee District, focusing on physicians‘ role 
barriers to adherence were found to be low income, and believing that ‗It makes no 
difference to their vision whether they took the drops or not‘, and relying on someone 
else for drop instillation (Castel et al., 2014, pp:459 ). 
 
Glaucoma medication compliance was assessed by Yoo, and Hwang (2015), they found 
that the most frequently found number of days of missing medication per month was 
one to four (43.4%). The most common reason for missing medication was 
forgetfulness (80.5%), followed by busy daily schedule, and complications of 
medication (1.1%). Older age, longer duration of treatment, higher knowledge about the 
glaucoma medication, and the presence of family support was significantly associated 
with a higher compliance score (p < 0.05). Sex, number and class of eye drops, and 
Glaucoma Symptom Scale(GSS) did not significantly affect compliance score.  
 
Patient age above 50 years and low level of education and negative family history of  
glaucoma were factors significantly associated with poor compliance (Abu Hussein  et 
al., 2015).   
Glaucoma Patient Expression of Medication Problems and Nonadherence study done by 
Slota et al., (2015). The purpose of this study was to examine if patient demographic 
factors influence self-reporting of medication side effects, difficulty with drop 
instillation and non-adherence to glaucoma therapy. The Results of this study  found 
that patients with lower health literacy were significantly less likely to express problems 
with side effects and eye drop administration during the visit. 
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2.5.2: Treatment Related Factors: 
The cost, complexity of taking multiple medications for multiple diseases, change in 
dosing schedules and side effects of medications are all well-known reasons for 
nonadherence (Nordstrom et al., 2005). If glaucoma patients have no external help this 
lead to complicate their medication adherence. Once-a day dosing with prostaglandin 
and beta-blockers have a better persistency (Nordstrom et al., 2005).  
The number of medications, the number of doses of each medication, and the specific 
instructions for medication taking have all been used to represent medication regimen 
complexity.  Higher daily dose frequency, especially of more than two administrations 
per day, is usually associated with increased glaucoma medication non-adherence. 
Forgetfulness, the main reason given by patients who missed one or 2 doses a week, 
inconvenience, and un affordability (Quigley et al., 2007). 
Taking a higher number of drops per day,  and taking a prostaglandin drug are 
considered a barrier to compliance in glaucoma patients this due to the side effects of 
prostaglandin eye drops (Castel et al., 2014). 
The frequency of instillation per day affected compliance significantly, although studies 
have shown that a single daily drug dose or combination is associated with better 
compliance rates  (Buchan et al.,2007). 
Results from the Collaborative Initial Glaucoma Treatment Study suggest that 75% of 
glaucoma patients will be on at least two types of eye drops two years following their 
initial diagnosis (Parrish et al., 2009).  
Factors leading to poor compliance were high drug cost, non-availability of drugs and 
side effects of medication also pose barriers to glaucoma medication adherence. The 
cost of glaucoma medications has been cited as a medication adherence barrier in most  
studies (Sleath et al., 2006; Tsai, 2009). 
Medication cost, limited health insurance, disease severity, and role of complicated 
dosing regimens, have varied effects based on the patient population studied and the 
definition of adherence. Poor medication adherence also is associated with decreased 
adherence to follow-up medical visit schedules (Tsai, 2009). 
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Polytherapy and lack of medical insurance could be contributing factors for 
noncompliance in glaucoma patients (Abu Hussein et al., 2015). 
Patients who expressed a problem with eye drop administration and with side effects 
were significantly more likely to express medication non-adherence to their 
ophthalmologist. Patients who reported greater  than 80% medication adherence during 
the interview were significantly less likely to express non-adherence to their 
ophthalmologist (Slota et al., 2015). 
2.5.3: Provider Related Factors: 
 
Adherence is better achieved where physician take proactive role in discussing with 
patient regarding their disease and use of medication. An open discussion regarding 
dosing, side effects, cost of medication, early and more frequent follow ups in the 
beginning usually help in developing a better understanding between patient and the 
physician. Communication between physicians and patients is a key factor in 
compliance for glaucoma patients (Taylor et al.,  2002).  
Communication in medical care is highly correlated with better patient adherence, and 
training physicians to communicate better enhances their patients‘ adherence (Kelly et 
al., 2009). Communication is thus an important factor over which physicians have some 
control in helping their patients to adhere (Kelly et al., 2009). 
Non-adherent participants with treatment were less likely to believe their eye doctors 
spent sufficient time with them, ask their eye doctor if they had any questions, knew of 
benefits to taking their glaucoma medication regularly (Stryker et al., 2010). 
Moreover factors leading to poor compliance were poor understanding of the doctor's 
instructions on how to use the drugs (Castel et al., 2014). However, Castel found that 
there is no association was found between the patient‘s relationship with the family 
physician and adherence to glaucoma treatment (Castel et al., 2014). 
A study published in (2015) conclude when providers educate glaucoma patients and 
assess patient views about glaucoma and its treatment, patients report higher medication 
self-efficacy. Providers should be aware that patients who ask more medication 
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questions may have less confidence in their ability to overcome barriers to adherence 
(Sleath et al., 2015). 
Okeke et al., (2009), found that patients are more compliant just before and just after 
doctor visit, with 55% of patients taking 75% of their required drops.  
2.5.4: Glaucoma related Factors: 
  
Diseases that are asymptomatic are more prone to poor patient compliance (Dimatteo et 
al., 2005). 
Poor compliance with treatment is known to influence glaucoma progression (Sleath  et 
al., 2011). 
compliance to topical anti-glaucoma medication has always been a major problem. This 
is greatly because treatment aims to stop or delay progression of the disease and there is 
absence of immediate visual restoration felt by the patient (Kass et all., 2002). 
 
Patients with glaucoma are largely not reminded by the disease process itself of the 
importance of taking medications as prescribed (Mantravadi et al., 2012). 
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Chapter Three  
Conceptual Framework: 
This chapter aims to critique the current theoretical models, in order to locate the 
research problem within the broader conceptual framework, and to explain health 
behaviors such as compliance with treatment.   
The researcher focused on the Health Belief Model, which is used in this study as a 
conceptual framework, its origin, development and components. 
 
3.1: Conceptual Framework Definition: 
Conceptual frameworks are particularly useful as organizing devices in empirical 
research. One set of scholars has applied the notion of conceptual framework to 
deductive, empirical research at the micro- or individual study level (Shields et al., 
2013). The conceptual framework used to predict the influences on compliance with 
ant-glaucoma treatment in specific population (glaucoma patients) is adaptive of the 
HBM.  
 
The theoretical framework which employed in this study is the Health Belief Model 
(HBM), which is the most common motivational model of compliance. 
It holds that; an individual's cooperation with health advice depends on the extent of the 
person's perception and susceptibility to the seriousness of the disease, treatment 
efficacy, and how to overcome barriers to compliance. Cause to action is added to the 
model to study the influence of external factors. 
 
The HBM explains the relationship between an individual‘s belief and behavior and 
defines the factors that motivate or demotivate an individual to do certain health-related 
actions, and the conditions that are effective in displaying health behaviors in particular 
(Sheeran, and Abraham, 1996). 
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The HBM assumes that an individual‘s perception of the susceptibility and severity of 
an illness produces the readiness to take a health action to reduce the health threat. The 
model includes four dimensions: (a) perceived personal susceptibility to a disease, (b) 
perceived severity if contracted the disease, (c) perceived benefits of a particular health 
action and (d) perceived barriers taking a particular health action (Sheeran, and 
Abraham,  1996).  
the Health Belief Model constructs, which include the severity of the disease, 
susceptibility to the disease, the benefits offered by a recommended action, and 
the barriers to taking said action. The mediating factors of self-efficacy (individual‘s 
perception of his or her ability to perform a recommended action) and cues-to-
action (external encouragements to perform a recommended action) have been added to 
the original four constructs. The Health Belief Model is a psychologically driven 
framework of concepts designed to explain and predict health behaviors by examining 
individuals‘ beliefs and attitudes regarding diseases and their treatments. It predicts 
preventive, screening, and/or treatment adherence based on value expectancy theory, 
which examines the value individuals place upon their current state of health and their 
expectancy that some action will maintain or improve that state (Strecher, and 
Rosenstock, 1997). 
 
For example, under the Health Belief Model theory, a person with glaucoma will be 
more likely to comply with treatment regimens if he or she places a high value on his or 
her current level of vision and also believes than an ocular hypotensive medication will 
prevent further vision loss. 
 
The Health Belief Model (HBM) was employed in the current study as theoretical 
framework. The questionnaire, interpretation and discussion were also depend on this 
model. The Health Belief Model (HBM ) served as the conceptual framework of this 
study. 
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3.2: Conceptual Framework Components: 
  
The following graph represents the relationship between the dependent variable 
"compliance with topical anti-glaucoma treatment" , and the independent variables that 
affect compliance;  
• Patient-related factors (socio demographic and economic factors). 
•Glaucoma related  factors  (Knowledge &Attitude toward  glaucoma) 
• Treatment related factors  
• Health provider-related factors  
 
 
 
 
 
Graph 3. 2: Conceptual Framework of the study. 
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3.3: Study Variables   
The dependent variable in the study was, compliance with topical anti-glaucoma 
medication, compliance has been defined as the extent to which patients‘ behaviors 
correspond with physician‘s recommendations. Compliance, as following the regimen 
on a daily basis. Patient compliance to their medication regimen is essential for treating 
most chronic diseases; glaucoma is no exception.  
Medication compliance: The extent to which a person‘s behavior coincides with 
medical or health advice.  
 
Dependent variable: 
 Adherence vs. Compliance  
1. The two terms are considered synonyms.  
2. Adherence: from patients‘ perspective (the fact of behaving according to a particular 
rule) 
3. Compliance: from health care providers‘ perspective (obeying rules or requests made 
by people in authority) 
 
Glaucoma adherence is difficult to measure. Patients routinely overestimate their level 
of adherence with self-report as compared with objective measures. Intraocular pressure 
is a poor surrogate for adherence because patients commonly increase their adherence in 
the day prior to visiting their eye care provider. (Kass et al., 2002) 
 
Independent Variables: 
The independent variables which are affecting compliance to topical anti-glaucoma 
medications are: 
 
* Patient related factors: socio-economic factors and socio-demographic characteristics 
like  Age, sex, marital status, educational level, place of residence, Family support, and 
visual acuity. Occupation and monthly family income (employment), insurance 
coverage, social status, cost of the treatment.   
 
31 
 
* Glaucoma related factors: severity and duration of glaucoma, duration of treatment, 
and comorbidities. Awareness and knowledge about glaucoma treatment, intraocular 
pressure, health beliefs and attitudes. 
 
* Treatment related factors: number, frequency, and side effect of medication(s), 
financial difficulties, and problem to obtain the medication(s).  
 
* Provider related factors: trust between patient and physician, enough information 
about glaucoma, treatments, and teaching patients about eye drop administration from 
physician and other health team. 
 
3.4: Study Variables Definitions (Operational Definitions(: 
 
3.4.1: Glaucoma:           
 
Glaucoma is a group of eye diseases which result in damage to the optic nerve and  
irreversible vision loss. A major risk factor is increased pressure in the eye (Casson et 
al., 2012).  
 
 3.4.2: Intraocular pressure (IOP): 
Intraocular pressure (IOP) is the pressure of fluid inside the eye. Tonometry is the 
method eye care professionals use to determine this. IOP is an important aspect in the 
evaluation of patients at risk from glaucoma. Most tonometers are calibrated to measure 
pressure in millimeters of mercury (mmHg) (Farandos et al., 2014).  
Normal eye pressure ranges from 12-22 mm Hg, and eye pressure of greater than 22 
mm Hg is considered higher than normal. 
 
3.4.3: Topical treatment:  
A topical medication is a medication that is applied to a particular place on or in the 
body, as opposed to systemically. (The word topical derives from Greek topikos, "of a 
place".) Most often this means application to body surfaces such as the skin or mucous 
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membranes to treat ailments via a large range of classes including creams, foams, gels, 
lotions, and ointments, such as eye drops applied to the conjunctiva (Psoriasis-
Treatmen, 2009) 
Treatment is defined as "medical care for an illness or injury" (Treatment, 2013), in this 
study, topical treatment is defined as the use of an approved pharmacologically active 
medicinal substance for the purpose of controlling Intra Ocular Pressure (Glaucoma). 
 
3.4.4: Compliance with prescribed topical anti-glaucoma treatment: 
                  
Compliance was defined using GTCAT after convert all negative statement to positive 
and choose cut point to be 3.33 any results of the total set of axis  less the cut point 
consider noncompliance, while results above this point were considered compliance.  
   
 
3.4.5: Glaucoma patient: 
  
A person diagnosed with glaucoma and receiving topical treatment (eye drops). 
 
The next table identifies the variables used in this study, operational definition, 
according to the literature. 
 Table 3.4: Operational Definitions of the Variables (Abu Hussein et al., 2015): 
Variable Operational definition 
Age (AGE) Age of the glaucoma patients at the time of survey and filling questionnaire,   measured 
in years.  
Level of 
Education 
Number of years formal schooling completed,  primary,  secondary,  graduated,  higher 
educated –Diploma,  PA,  Master .  
 
Awareness 
Having knowledge about the danger of glaucoma and also about the benefit of 
compliance to topical medication and ophthalmic screening, awareness implies 
knowledge gained through means of information, understanding of, appreciation of, 
recognition of,  attention to.  
 
Family income 
(INC) 
Total family income per month by NIS: total compensation received by 
all family members age 15 or older living in the same household for at least one year. It 
may include business, farming, rent,  interest, wages. 
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Health 
insurance 
Having any type of health insurance, governmental, UNRWA, private or other types of 
insurance that protect the financial well-being of the individual by covering health 
services costs (screening, follow up, and required treatment).  
 
Health care 
provider 
A person who helps in identifying or preventing or treating illness or disability or health 
services to health care consumers.  
 
 
 
Family 
History of 
glaucoma 
Having a first degree close relatives with glaucoma like: father, mother, and brethren.  
Number of 
Doses per 
day (dosing 
frequency) 
The number of times per day for which medication was prescribed to glaucoma 
patients. 
Side Effects of 
glaucoma 
medication 
Undesirable effect of  medication, most common being bitter taste, stinging, redness 
and dry eye. 
High Cost of 
drug 
Cost over glaucoma patient willingness and ability to pay  
Single drug Use of one eye drop 
Combined 
drug 
Use of two or more eye drops 
Comorbidity 
 
Patient has any physical impairment  that may affect compliance with topical anti-
glaucoma treatment these include (DM, HTN, CAD, arthritis), beside having difficulty 
in instilling eye drop like: difficulty aiming the drop, squeezing the bottle, blinking, and 
seeing the tip of the bottle. 
  
Visual acuity Sharpness of vision, especially as tested with a Snellen chart. 
Normal visual acuity based on the Snellen chart is 20/20. 
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Chapter Four  
Methodology 
 
4.1: Introduction: 
 
This chapter aims to outline the methodology, explain and define the study‘s 
design and setting, also to explore the participants sample size and the choice of target 
sample. Study tool, followed by a statistical method to analyze the data.  
 
4.2: Study Design:  
This study used a quantitative, descriptive and cross-sectional survey design within 
SJEHG which was carried out on glaucoma patients, to assess the level of glaucoma 
patient compliance to topical anti-glaucoma medication. And to determine the factors 
that influence glaucoma treatment adherence with using of topical anti-glaucoma in 
order to develop an intervention for a specific population (glaucoma patients) and to 
help them to enhance their compliance. The study was conducted between November 
2016 and January 2017.  
This method was easily applicable and cost effective. Also it is consider  a technique  
which enables the researcher to collect numerical data and answer the research question 
in a short period of time (Ethridge, 2004). 
  
4.3: Study Settings: 
The settings of data collection, were SJEHG outpatient glaucoma clinics in three cities 
Jerusalem in the middle, Hebron in the south, and Anabta in the north.  
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4.4: Study Population:  
 
The study population was comprised of glaucoma patients attended outpatient glaucoma 
clinics to be treated, at SJEHG in (Jerusalem, Hebron, and Anabta). In 2016, around 
1600 patients were treating at the SJEHG, of those who attended, 332 targeted to reach 
320 patients were selected (convince), while they waited to see the specialist, and  
invited to  participate in this study.  
 
4.4.1: Inclusion criteria: 
The criteria of sample selection were based on the following criteria which were:  
 Aged 18 years and older.  
 They had been diagnosed as having chronic glaucoma, by a consultant 
ophthalmologist. 
 They had been prescribed medication for glaucoma, and were taking daily doses of 
topical glaucoma treatments for at least one year. 
 Agreed to participate in the research and data collection. 
 
4.4.2: Excluded criteria: 
 Were too sick to be interviewed. 
 Participants who had eye surgery related to glaucoma within 3 months of the date of 
medical chart review were excluded. 
 Especial condition, such as senile dementia, was present which rendered them 
unsuitable for participation.  
 
4.5: Mechanism of Sample Selection (Sampling method): 
Patients who were attending the out-patient glaucoma clinics at 3 cities (Jerusalem, 
Hebron, and Anabta in Palestine) and coming for a follow-up within the study period 
(three month from November 2016 to January 2017), were invited to join this study, 
interviewed and their medical records were reviewed.  332 invited to join study, twelve 
of them did not participate: 4 were physically too ill, and 8 refused to co-operate. 
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A convince sample of glaucoma patients was used to select the participants from three 
outpatient clinics. The researcher selected starting point (M: first patient attended 
glaucoma clinic in each city) and picked the subject until 320 subject were gathered 
from all clinics of SJEHG (Jerusalem, Hebron, and Anabta).  
 
4.6: Sample Size: 
The sample was calculated depending on the review of outpatient glaucoma clinics in 
the last two years (2015/2016). I observed and estimated the total number of patients 
who visited the outpatient clinics for follow up, or were newly diagnosed with 
glaucoma. According to the estimated number of patients and after revising it with a 
statistical specialist. The minimum sample size was calculated using a formula used to 
estimate the sample size for a single population (Daniel, 1999):  
n = (Z1− α /2) 2 (p × q) /d 2  
Where:  
 
-/2 = the standard normal variable at (1- ) % confidence level and is the level 
of significance. At a 95% confidence level, the value of this parameter is 1.96 that was 
used in the study.  
 
 
 
 
Since there was no information from similar studies, past studies, or studies done on 
similar populations and no pilot study about the proportion was done, a conservative 
sample estimate was used assuming that the sample was independent and randomly 
selected. 
 n=(Z1−α2)2(p×q)/d2=(1.96)2×0.5×0.5(0.05)2=384.16≈384  
As the estimated total study population is < 10,000, correction formula was then used. 
Therefore,  
nf=n/1+n/N=384/1+384/1600=384/1.24=309.6≈310  
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Where:  
 
n is >10,000  
 
 
I  added three percent contingency (310×3% =9.3) for non-respondents to the computed 
value. Finally, the minimum required sample size was calculated to be 310 + 10 = 320.  
I divided the estimated total number of glaucoma patient who attended SJEHG by the 
lowest number of glaucoma patient who attended the Hebron glaucoma clinic which 
was 250 patients (1600/250; the result was 6.4). Then the number of sample was 
divided by the number of patients in each clinic which represents 6.4 quotas from 
divided 320/6.4=50 subject in each quota, I gave Jerusalem outpatient glaucoma clinics 
which had 1000 glaucoma patients 4 quotas from the total sample size (50*4=200). 
Hebron outpatient glaucoma clinic contained nearly 250 glaucoma patients given one 
quota (50*1=50). At the Anabta outpatient glaucoma clinic the researcher selected 70 
patients randomly from 350 patients which represent one and half quota (50*1.5=75). 
 
4.7: Study Tool: 
The Questionnaire was the instrument of research, because it is an inexpensive way to 
gather data from a large number of respondents. (Ethridge, 2004) A pre-used and 
standardized questionnaire was used to collect the data from the study sample. The 
psychometrics of the Glaucoma Treatment Compliance Assessment Tool (GTCAT), 
questionnaire designed by An American Ophthalmological Society (Mansberger et al., 
2013), to assess adherence with glaucoma therapy. This questionnaire includes items 
related to the six Health Belief Model constructs, as well as other relevant information, 
such as age, medical history, gender, income, education levels, and type of insurance 
coverage. Most questions include a 5-interval Likert scale response with anchoring 
definitions (eg: 1=absolutely disagree, 5=absolutely agree).  
  
The GTCAT is questionnaire to study glaucoma medication adherence. It was 
developed using expert opinion, previous studies regarding adherence in glaucoma 
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patients done by Granstrom (1982), Kass et al., (1986), and Winfield et al., (1990), and 
the Health Belief Model. The Health Belief Model is a psychologically driven 
framework of concepts, designed to explain and predict health behaviors by examining 
individuals‘ beliefs and attitudes regarding diseases and their treatments. It predicts 
preventive, screening, and/or treatment adherence based on Value Expectancy Theory; 
which examines the value that individuals place upon their current state of health and 
their expectancy that some action will maintain or improve that state. (Strecher, and 
Rosenstock, 1997) 
 
4.7.1: Validity  
 
Validity is the degree to which any instrument succeeds in describing or quantifying what it 
is designed to measure (Jonathan, 2007).  And validity refers to how well a test measures 
what it is purported to measure. 
Questionnaire  was evaluated by using data from a cross-sectional study with focus 
groups (n = 20) and a prospective observational case series (n=58). Principal 
components analysis provided assessment of construct validity. Predictive validity was 
high, with several Health Belief Model questions significantly associated (P <.05) with 
adherence and a correlation coefficient (R (2)) of .40 (Mansberger et al., 2013). 
 
4.7.2: Reliability  
 
Reliability is the degree to which an assessment tool produces stable and consistent 
results. Also, reliability of a measure is the degree to which a measurement technique 
can be depended upon to secure consistent results upon repeated application (Jonathan, 
2007). 
 
The reliability of the tool in this study was estimated using Cronbach's alpha coefficient 
(Cronbach‘s alpha). ―Alpha was developed by Lee Cronbach in 1951 to provide a 
measure of the internal consistency of a test or scale; it is expressed as a number 
between 0 and 1. Internal consistency describes the extent to which all the items in a test 
measure the same concept or construct, and hence it is connected to the inter-relatedness 
of the items within the test‖ (Tavako, 2011).  
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 Mansberger et al., (2013) repeated the questionnaire after 3 months for test-retest 
reliability. They evaluated predictive validity using an electronic dosing monitor as an 
objective measure of adherence. Focus group participants provided 931 statements 
related to adherence, of which 88.7% (826/931) could be categorized into the constructs 
of the Health Belief Model. Perceived barriers accounted for 31% (288/931) of 
statements, cues-to-action 14% (131/931), susceptibility 12% (116/931), benefits 12% 
(115/931), severity 10% (91/931), and self-efficacy 9% (85/931). The principal 
components analysis explained 77% of the variance with five components representing 
Health Belief Model constructs. Reliability analyses showed acceptable Cronbach's 
alphas (>.70) for four of the seven components (severity, susceptibility, barriers [eye 
drop administration], and barriers [discomfort]), which may be considered as 
acceptable. Test-retest reliability was 90%. The GTCAT shows excellent repeatability, 
content, construct, and predictive validity for glaucoma adherence (Mansberger et al., 
2013). 
The study tool (questionnaire) was used by Kowal  et al., (2008) to study the obstacles 
to medication compliance for patients with glaucoma,  in glaucoma out-patient clinic of 
the Department of Ophthalmology, Medical University, Lublin, Poland and regional 
out-patient clinics.   
 
For the purpose of this study, the tool was adapted and translated into Arabic, by two 
specialist ophthalmic staff nurses, reviewed by the only glaucoma specialist in Palestine 
whose works at SJEHG Dr. Amer Muhsen and SJEHG nursing coordinator Mr. Ahmad 
Ma'ali PhD. Then it was given to the quality manager Mr. Waleed AL-Kateeb MD at 
SJEHG to translate back to English to make sure we didn't lose the value and the 
meaning in the translation in order that  the tool is  still valid. Also the questionnaire 
was inspected by an Arabic lingual inspector to evaluate its language level suitability 
and to correct if for any mistakes in grammars or dictation. Then it was given  randomly 
to a limited number (5) of glaucoma patients in glaucoma clinics at Jerusalem, Hebron, 
and Anabta to give me their recommendations or suggestion to make all questions in the 
questionnaire clear and easy to be filled even by patient or by researcher assistants. This 
was before starting the pilot study. The final structure consisted of 68 closed and open-
ended questions divided in two parts, which could be completed within 20-28 minutes, 
and it had been numbered for entering data and analysis easily. 
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Section one of the questionnaire included 21 questions concerning social demographic 
and personal characteristics of the participants, such as the age, marital status, 
educational level, occupation, family income, if the participant has any type of health 
insurance.  
 
Section two of the questionnaire objectives were to measure knowledge and attitude 
toward compliance and glaucoma, through asking the participants 49 questions were 
consisted in this part (1.2.3.4.5.6.7.8.9.10.11.12). 
Also questions about the benefits of compliance with topical anti-glaucoma treatment, 
the questions of this part had statements as stem followed by variation of answering, 
strongly disagree, disagree, don‘t know, agree, strongly agree.     
The questions need closed answer options, by tick marked under the choice that best 
described their beliefs and opinions from multiple choices.  
Questions aimed to measure the extent to which participants agree with positive 
statements regarding their beliefs about the factors that affect their compliance with 
topical anti-glaucoma treatment, these barriers were identified by listing 18 possible 
barriers, divided into four parts, personal related barriers include 29 statements, anti-
glaucoma treatment related barriers 11 statements, glaucoma related barriers 4 
statement, other statements 45.46.47 to measure the health provider related barriers .  
 
A 5-point Liker scale used in this section to assess intensity of agreement of the 
glaucoma patient, through marked the statement with any level of agreement, by putting 
(x) in the box regarding their beliefs and opinion. 
 
Some of the statements which are listed in this part to measure the potential of personal 
related barriers were (1.2.3.4.5.6.7.8.9.10.11.12.20.21.22.23.24.25). 
Barriers related to topical anti-glaucoma treatment (13.14.15.26.27.28.29.30.31.32.33). 
Questionnaire constructed and reviewed by the specialist, (annex B), and tested for the 
reliability and validity, through a pilot study (annex D), then it was approved by the 
instructor to be ready for data collection.  
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4.8: Pilot Study, Validation of the questionnaire: 
 
The pilot study was conducted to help the researcher examine the feasibility of the 
approach that was intended to be used in a larger scale study, to design a research 
protocol, to assess whether the research protocol was realistic and workable, and to 
establish whether the sampling frame and technique were effective. 
 
After developing the questionnaire, a pilot study was conducted on 5% from the sample 
(17) patients who were treated at SJEHG (Jerusalem middle 10, Hebron south 3, Anabta 
north 4). The Questionnaire was filled through face-to-face interview, patients was  
asked for feedback, and testing of the questionnaire, wording accuracy, readability, 
simplicity, content and face validity, also to estimate the time required to fill the sheet. 
Pilot study was carried out from  26 October to 30 October 2016. Patients who 
participate in pilot study weren't included in the study.  
 
Statistically, all statements in the questionnaire were numbered and coded, to easily 
enter the generated and gathered data from the participants then data was analyzed. The 
pilot study was analyzed, and based on the reliability alpha; the instrument revealed 
high Cronbach‘s alpha values more than 73.3% as shown in the next table.  
 
Table 4.8: Represent the results of Cronbach‘s alpha values. 
 Barriers Cronbach's Alpha 
1 Knowledge of  patient's  about glaucoma disease % 51. 2 
2 Awareness of glaucoma  patient's to the severity of 
their  disease (glaucoma) 
% 93. 6 
3 Barrier to compliance with treatment  % 31. 9 
 Cause to action questions and Self reported 
compliance 
% 76. 8 
 Patient –physician relationship % 63. 3 
Total degree   % 73. 3 
 
Based on the results of the pilot study, the necessary adaptation and some modification 
occurred to some changes, some changes were adopted by the researcher, following the 
pilot study.  A result of the researcher obtaining a deeper understanding of the reality on 
the ground. After validation of the Arabic translation of the Glaucoma Treatment 
Compliance Assessment Tool (GTCAT), approval to conduct the survey was obtained 
from the supervisor of the thesis, at Al-Quds University, who has been involved and 
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consulted at every step. His advice has been valuable, and his observations and remarks 
were considered and followed, throughout the study and subsequent reporting. 
 
4.9: Data Collection: 
 
The scientific method applied in data collection process, after defining problems and 
issues, several meetings were held with interviewers " 6 nurse students", discussed the 
feedback of the pilot study, to improved the performance, focused on the objective of 
the study  to administer the questionnaire . 
The mechanism of sample selection explained, and terms of choosing the participants, 
and how to fill out the questionnaire accurately, and the interviewers were able to 
clarify all questions for glaucoma patients through face-to-face interview.  
Starting points in the process of filling the questionnaires in every clinics selected, a 
plan of daily work developed, in order to complete the filling of 320 printed 
questionnaires 332 of those patients who attended where selected (convince) . As 
planned in the process of selecting the sample, in November 2016, we began the process 
of filling out the questionnaires. 
 
All participants were given a full explanation of the methodology and purpose of the 
research, assurance of confidentiality of all information. Participants were also assured 
that their participation in the study was voluntary; they could refuse to participate at any 
time during the interview without affects their treatment. 
Participants were invited to private office interview, using pre-tested validated 
questionnaire available in Arabic. One to one interview was done by trained 
interviewers. The interview took around 28 minutes and was usually done on one of the 
patient‘s follow-up visits.  The interviewer also tried to stress the value of accurate 
information rather than gain positive impression and shared the concept that failure to 
take medication as prescribed due to many personal, social, and economic factors is a 
common problem. Medical charts of the patients were reviewed to abstract IOP of both 
eyes, and visual acuity of glaucoma patients.  
After confirming the validity of the filling of all questionnaires, data cleaned,  reviewed 
and audited, the data generated on the questionnaires were numbered and validated 
manually for errors and entered for analysis by SPSS version18.  
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4.10: Statistical method / Data Analysis: 
The quantitative data sets collected from participants were cleaned, coded, and entered 
into the Statistical Package for the Social Sciences (SPSS 18).  
All coding and data entries were verified, frequency distributions were calculated for all 
variables, and incorrect codes were identified and corrected. 
SPSS was also used for descriptive statistics on the characteristics of research 
participants and to analyze and interpret the results.  
Descriptive statistics, including percentages, means, standard deviation (SD), were 
calculated. ANOVA test was used to recognize association between knowledge  about 
glaucoma and demographic factors, sex, age, marital status, education….etc.  
Differences between means of variables by compliance to anti-glaucoma topical 
treatment were calculated with Chi -Square test . 
Multiple linear regression (stepwise  regression) used to factors that most affect the 
degree of compliance, analysis with topical glaucoma treatment -use compliance as the 
dependant variable was performed for the entire participants,  these were hypothesized 
to be associated with compliance with topical glaucoma treatment -use suggested in the 
literature. 
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Chapter Five: Results  
Research Findings 
 
5.1: Introduction:   
This chapter aims to review the findings of study. The first section, biographical 
data such as age, gender, marital status, educational level, household income, health 
insurance,…..etc findings related to glaucoma patient characteristics and compliance 
with topical anti-glaucoma treatment were represented.   
 
5.2: Demographic characteristics of respondents:  
 
5.2.1: Age of participants: 
Most age group frequencies of the sample was between the age (61-70) years (23.1%), 
followed by (20.0%) were between (51-60) years, and the lowest age group was from 
(20-30) (12.5%) as (5.2.1) graph shows: 
 
 
 
Graph 5.2.1: Represent the frequencies of age group of the sample respondents. 
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5.2.2: Gender of the participants.  
Graph (5.2.2), shows the frequencies of  sample gender : the sample  consists of (320) 
respondents, (178) male (55.6%), and (142) female (44.4%). 
 
 
Graph 5.2.2: Represent the frequencies related to the gender of participants. 
 
5.2.3: Marital status of the participants: 
Marital status of the participants is presented in the table below (5.2.3). Most of the 
participants (60.6%) were currently married, followed by (17.8%) were widowed, 
(15.9%) were single, and those divorced were the remainder (5.6%), as (5.2.3) table 
shows:  
Table 5.2.3: Frequencies of the distribution of marital status of the sample: 
Marital  Status 
  Frequency Percent 
Single 51 15.9% 
Married 194 60.6% 
Divorced 18 5.6% 
Widowed 57 17.8% 
Total 320 100.0% 
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5.2.4: Educational level: 
Regarding to their educational attainment, the sample was generally educated, since 
(19.7%) have university graduated with BA, (12.5%) were with diploma, and those with 
primary and secondary school were (30.0%), (24.1%) respectively,  (2.2%) were with 
master degree, and (11.6%) of the sample were illiterate, as (5.2.4) table shows: 
 
Table 5.2.4:  Frequencies of the distribution of  Educational level of the sample: 
Educational Level 
  Frequency Percent 
Illiterate 37 11.6% 
Primary School 
96 30.0% 
Secondary School 77 24.1% 
After School 
Education (Diploma, 
BA, Master degree) 
110 (12.5%; 19.7%; 2.2%) 
34.4% 
Total 320 100.0% 
 
5.2.5: Work status of the participants: 
According to their work status, (32.8%) of the sample were employed, (31.9%) were 
unemployed, (22.8%) housewives, and those retired were rated (8.4%), as graph (5.2.5)  
shows:  
 
Graph 5.2.5: Represent frequencies of the distribution of  work status of the 
participants. 
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5.2.6:  Monthly Income of the participants (glaucoma patients):  
The following graph (5.2.6), represents the values of the families income, (38.8%) of 
the sample their incomes between (2500-3499) NIS monthly, (30.0%) between (1500-
2499) NIS, whereas (15.3%) their income were between (3500-4499) NIS, (5.0%) 
between (4500-5499), and the remainder (10.9% ) estimated their income more than 
(5500) NIS.  
 
 
Graph 5.2.6: Percentages of Monthly  Household Income by NIS. 
 
5.2.7: Residence of the participants (glaucoma patients): 
Most of the participants were from rural area (41.9%), followed by (38.8%) were from 
cities, and (19.4%) were from refugee camps as (5.2.7) graph show. 
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Graph 5.2.7: Represents frequencies of glaucoma patient participants Address/ 
Residence  
 
5.2.8: Having Health Insurance:  
Table (5.2.8), shows the percentage of the health insurance as seen high percents of the 
participants have health insurance (80.0%), while (20.0%) without any type of 
insurance.    
 
Table 5.2.8: Represent the percentage of health insurance for the family": 
Health Insurance Frequency Percent 
Valid Yes 256 80.0% 
No 64 20.0% 
Total 320 100.0% 
 
 
5.2.9: Type of Health Insurance: 
Most of the participants have public insurance (53.5%), (23.8%) have UNRWA 
insurance,  (14.8%) having private insurance, and (7.8%) have other type of insurance, 
as (5.2.9) graph  shows: 
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Graph 5.2.9: Represents the frequencies of health insurance type.  
 
5.2.10: Health insurance coverage of glaucoma checkup and treatments: 
Glaucoma patients didn‘t get coverage for their routine checkup, nor their lifelong 
treatments with a percent (52.0%), while (16.8%) get  coverage around 50% of the total 
cost, (17.2%) of glaucoma patients get coverage around 25% of the total cost, only 
(5.1%) of patients get coverage around 75% of the total cost, while (9%) of patients 
didn‘t know if their insurance cover their routine checkup or their treatments, as (5.2.10) 
graph shows: 
 
 
Graph 5.2.10: Represent The frequencies of the family insurance coverage for  the cost 
of  glaucoma checkup and treatments. 
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5.2.11: Number of eye glaucoma medication prescribed:  
(40.6%) of glaucoma patients were using two types of glaucoma treatments (eye drop) 
daily, while (36.3%) were using three types of glaucoma treatments daily, and the rest 
(23.1%) were using one type of glaucoma treatments daily, as (5.2.11) table shows: 
Table 5.2.11:  Represent the frequencies of glaucoma medication number prescribed for 
the participants.   
Number of eye glaucoma 
treatment (eye drop) 
Frequency Percent 
  One type daily 74 23.1% 
Two types daily 130 40.6% 
Three types and more 
daily 
116 36.3% 
Total 320 100.0% 
 
5.2.12: Frequency of using eye drops per day: 
(49.0%) of the participant were using their glaucoma treatments two times a day, while 
(37.9%) were using their glaucoma treatments three times daily, and (13.1%) were 
using their treatments once a day, as (5.2.12)  table shows: 
Table 5.2.12: Represent the frequencies of using eye drops per day by glaucoma 
patients: 
Frequency of using eye 
drops per day 
Frequency Percent 
 Once a day 42 13.1% 
Two times a day 157 49.1% 
Three times a 
day 
121 37.8% 
Total 320 100.0% 
 
 
5.2.13: Duration of glaucoma disease: 
As shown in the table (5.2.13)  highest percent of the participants (44.1%) had the 
disease from 1-5 years, (25.9%) had the disease from 6-10 years, and the lowest 
frequency was (8.8%) of the respondent had the disease for more than 20 year. 
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 Graph 5.2.13: Represent the frequencies of glaucoma disease duration for the sample. 
 
5.2.14: Family History of Glaucoma: 
Related to family history of glaucoma (69.7%) of the respondents didn‘t have any 
family history of glaucoma, and 30.3% had positive family history of glaucoma, as 
(5.2.14) graph shows: 
 
 
Graph 5.2.14: Represent the frequencies of the family history of glaucoma. 
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5.2.15: Systemic comorbidity such as hypertension, diabetes, and ischemic heart   
disease:  
Around half of the participants had other systematic disease beside glaucoma with a 
percent of (55.0%), and (45%) just had glaucoma disease only, as (5.2.15) table shows: 
Table 5.2.15: Represent the frequencies of systemic comorbidity such as hypertension, 
diabetes, and ischemic heart   disease for the respondents. 
Systemic comorbidity Frequency Percent 
 Yes 176 55.0% 
No 144 45.0% 
Total 320 100.0% 
 
 
5.2.16: Transportation and access between the place of residence and SJEHG:  
Table (5.2.16), shows that the majority of the respondents had transportation to SJEHG 
(85.4%),  and only (14.6%) didn‘t have transportation to SJEHG, despite that glaucoma 
patients suffer from political condition closure of roads and difficulties to reach 
Jerusalem due to occupation and they have to cross check points to access their 
outpatient clinic. 
Table 5.2.16: Represent the frequencies of transportation and access available between 
the place of residence and SJEHG. 
Transportation Frequency Percent 
Valid Yes 275 85.9% 
No 45 14.1% 
Total 320 100.0% 
 
 
5.2.17:  Glaucoma patients visual acuity:  
Graph (5.2.17) illustrates that around half of the participants 54.7% have low vision 
which defined as the (best-corrected visual acuity less than 6/18 in the better-seeing eye 
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to light perception, while blindness (complete lack of light perception, and is recorded 
as "NLP," an abbreviation for "no light perception) according to (WHO) was 30.6%, 
and 24.1% respectively. While 45.3% of the sample has vision near to normal, (6/12 to 
6/6). 
 
 
 
Graph 5.2.17: Represent the frequencies of visual acuity of the participants (glaucoma patients). 
 
5.2.18: Whose refer glaucoma patients to SJEHG:  
The majority of glaucoma patients discover their disease by chance while they came to 
check their vision self referred (46.9%), and (40.9%) referred from governmental 
hospital, (12.2%) referred from private ophthalmic physician, as (5.2.18) graph shows: 
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Graph 5.2.18: Represent the frequencies of  the distribution of  Whose refer glaucoma 
patients to SJEHG. 
 
5.2.19: Two most recent intra-ocular pressure results: 
Table (5.2.19), shows that the mean for two most recent intra-ocular pressure results 
(Right Eye) previous visit for glaucoma patients sample was (20.6), while the two most 
recent intra-ocular pressure results (Right Eye) current visit was (17.77). And related to 
the two most recent intra-ocular pressure results (Left Eye) previous visit was (19.15), 
and the two most recent intra-ocular pressure results (Left Eye) current visit was 
(19.63). 
 
Table 5.2.19: Represent the mean and standard deviation for the two most recent intra-
ocular pressure results for the sample of glaucoma patients: 
Descriptive Statistics 
Two most recent intra-ocular pressure (IOP) results  Mean Std. 
Deviation 
Two most recent intra-ocular pressure results (Right Eye) Previous 
visit 
20.63 8.60 
Two most recent intra-ocular pressure results (Left Eye) Previous 
visit 
19.15 7.81 
Two most recent intra-ocular pressure results (Left Eye)Current 
visit 
19.63 8.32 
Two most recent intra-ocular pressure results (Right Eye) Current 
visit 
17.77 7.83 
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5.3: Compliance level: 
Table (5.3) shows, that the majority of the respondents (71.6%) were noncompliant, 
while only (28.4%) of the sample was compliant.  
 
Table 5.3: Compliance level to topical anti-glaucoma treatments for the respondents.  
 Total Compliance Level 
  Frequency Percent 
  Noncompliant 229 71.6% 
Compliant  91 28.4% 
Total 320 100.0% 
 
 
5.3.1: Self reported compliance level: 
Based on answers of statements (44.45), and using same cut point I measured the 
compliance level of the participant, and I found that they exaggerated their compliance 
level as table (5.3.1) shows, that noncompliance level was 41.9% compared to the total 
predicted noncompliance level 71.6%,  which mean that we can't only rely on self 
reported  to evaluate compliance level, because patients usually underestimated their 
noncompliance level.  
 
Table 5.3.1: Represent self report compliance level: 
Self reported of compliance level  
  Frequency Percent 
  Noncompliant 134 41.9% 
Compliant   186 58.1% 
Total 320 100.0% 
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5.4.1: Participants’ Knowledge about glaucoma:  
5-point Likert scale used to measure Knowledge about glaucoma, entered data were 
coded as followed: 
1. Strongly disagree 
2. Disagree 
3.Dont know  
4. Agree 
5. Strongly agree  
Then after analysis those respondents with mean (1-1.80) considered as strongly 
disagree,  and those with mean (1.81–2.60 disagree), (2.61–3.40) moderate, (3.41–4.20) 
agree, (4.21–5.00) strongly agree.   
By calculating the mean and standard deviation for the sample of glaucoma patients 
response toward their knowledge about glaucoma, table (5.4.1) shows that the total  
agreement level related to their knowledge about glaucoma disease was moderate with a 
mean (M=3.25). The statement that have the highest mean (M=3.81) was "Vision lost 
from glaucoma is permanent", that mean 76.2% of the participants  know that. Then the 
statement " The reasons people get glaucoma is not well understood" with a mean 
(M=3.56), that mean 71.2% of the participants  know that. While the statement that had 
the lowest mean (M=2.73) was " Glaucoma is always genetic"  that mean only 48.6% of 
the participants know that. 
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Table 5.4.1: Represent  the respondents  knowledge level related to glaucoma: 
 
 
5.4.2: Participants perception of severity of their disease (glaucoma) 
and the benefits of using treatments: 
In this part the results about opinions and agreement of the glaucoma patient toward 
their condition related their disease and the benefits of treatment.   
Table (5.4.2.1), and table (5.4.2.2) represents glaucoma patient's perception of their 
disease severity and their opinion related to the benefits of using treatments.  
 In this study a question about what is the awareness of glaucoma patient's to the 
severity of their  disease (glaucoma)? To answer this question means and standard 
deviation of items were calculated, as shown in the (5.4.2.1) table: 
 
 Knowledge Mean Percent % Std Agreement 
level with 
sentence 
8 Vision lost from glaucoma is permanent. 3.81 76.2 0.84      Agree 
12 The reasons people get glaucoma are not well 
understood. 
3.56 71.2 0.78 Agree 
10 Glaucoma can be caused by  an eye injury. 3.48 69.6 0.88 Agree 
5 Being older increases the chances of developing 
glaucoma. 
3.42 68.4 1.08 Agree 
4 A person can have glaucoma and not know it. 3.35 67 1.08 Moderate 
7 Glaucoma can occur with normal eye pressure. 3.30 66 0.79 Moderate 
9 Glaucoma can be caused by diabetes. 3.25 65 0.84 Moderate 
2  My personal knowledge of  the symptoms of 
glaucoma is excellent 
3.07 61.4 1.15 Moderate 
6 Eye pain is a common  symptom of glaucoma. 3.07 61.4 1.25 Moderate 
11 Blindness is not a possible result of glaucoma. 2.99 59.8 1.06 Moderate 
1 My personal knowledge of  the risk factors for 
glaucoma is excellent    
2.94 58.8 1.10 Moderate 
3 Glaucoma is always genetic 2.73 54.6 1.02 Moderate 
 Total  agreement level related to their knowledge 
about glaucoma disease 
3.25 65 .35 Moderate 
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Table 5.4.2.1: Represent the results of glaucoma patient‘s perception to the severity of 
their condition (disease): 
 
 
Total agreement level for the participants related to their perception for the level of their 
disease severity was moderate with a mean (M=2.96). The statement that have the 
highest mean (3.27) was  "All of my vision could be lost due to glaucoma",  that mean 
65.4% of the participants  know that. Then the statement " If I lost the same amount of  
vision over the next five years as I have over the past five, it would have no effect on 
my quality of life" with a mean (M= 3.10) ), that mean 62% of the participants know 
that. While the statement that had the lowest mean (M= 2.49) was "I have lost none of 
my vision due to glaucoma", that mean only 49.8% of the participants  know that. 
 
Table (5.4.2.2) shows the participants total agreement level related to their perception 
for  the  benefits of using treatments with a mean (M=3.31). The statement that had the 
highest mean (M=3.47)  was " Major vision loss from glaucoma can be prevented with 
treatment", that mean 69.4% of the participants  know that. Then the statement "Eye 
drop medication can totally control the negative progress of my glaucoma"  with mean 
(M=3.32), that mean 66.4% of the participants  know that. While the statement that had 
the lowest mean (M=3.14) was " I don‘t think I will go blind in 10 years if I do use my 
eye drops", that mean  62.8% of the participants  know that. 
 
 Severity Mean Std Agreement level 
with sentence 
18 All of my vision could be lost due to glaucoma 3.27 1.11 Moderate 
19 If I lost the same amount of  vision over the 
next five years as I have over the past five, it 
would have no effect on my quality of life. 
3.10 1.11 Moderate 
16 The level of my eye disease is not severe. 2.98 1.16 Moderate 
17 I have lost none of my vision due to glaucoma. 2.49 1.07 Moderate 
 Total agreement level related to their perception 
for the level of their disease severity  
2.96 .63 Moderate 
59 
 
 
 
Table 5.4.2.2: Represents the perception of the respondents (glaucoma patients) of the 
benefits of using glaucoma treatment: 
 
 
5.4.3: Participants Susceptibility: 
Table (5.4.3), shows the participants total agreement level related to their perception for 
the susceptibility to get glaucoma with a mean (M=3.21).  The statement that had the 
highest mean (M=3.75)  was " I  need to take drops", that mean 75% of the participants  
know that. Then the statement" I think I will go blind in 5 years if  I do not use my eye 
drops" with mean (M=3.68), that mean 73.6% of the participants  know that. While the 
statement that had the lowest mean (M=2.53) was " I was not surprised to have gotten 
glaucoma ", that mean  50.6% of the participants  know that. 
 
 
 
 Benefits Mean Std Agreement 
level with 
sentence 
13 Major vision loss from glaucoma 
can be prevented with treatment. 
3.47 0.89 Agree 
15 Eye drop medication can totally 
control the negative progress of my 
glaucoma. 
3.32 1.12 Moderate 
14 I don't  think I will go blind in 10  
years if I DO use my eye drops 
3.14 1.09 Moderate 
 Total agreement level related to their 
perception for  the  benefits of using 
treatments 
3.31 .71 moderate 
60 
 
Table 5.4.3: Represents the Participants perception of the Susceptibility to get the 
disease (glaucoma):  
 
 
5.4.4: Barrier to compliance with glaucoma treatments: 
What are a barriers to compliance with treatment? To answer this question means and 
standard deviation of items were calculated and showed that the total agreement level of 
the participant  related to their perception of treatments barriers was moderate with a 
mean (M=3.11).   
The statement that had the highest mean and moderate agreement was  "Sometimes the 
drops aren‘t with me when it is time to take them "with mean (M=3.34), that mean 
66.8% of the participants  know that. Then the statement" Sometimes I forget to use my 
drops " with mean (M=3.26), that mean 65.2% of the participants  know that. While the 
statement that had the lowest mean (M=2.76) was " I suffer from side effects when 
using my drops ", that mean  55.2% of the participants  know that. 
 Susceptibility Mean Std Agreement level 
with sentence 
25 I  need to take drops. 3.75 1.10 Agree 
20 I think I will go blind in 5 years if I DO 
NOT use my eye drops. 
3.68 1.09 Agree 
23 I am more susceptible to  blindness than 
other people my age. 
 
3.36 1.09 Moderate 
21 I think I will go blind in 10 years if I DO 
NOT use my eye drops 
3.33 1.01 Moderate 
24 I think I will develop other  potentially 
blinding eye diseases. 
2.92 .95 Moderate 
22 I was not surprised to have gotten 
glaucoma. 
2.53 1.18 Moderate 
 Total agreement level related to their 
perception for the susceptibility to get 
glaucoma 
3.26 .45 Moderate 
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Table 5.4.4: Represent the  barriers to compliance with glaucoma treatment: 
 
 
5.4.5: Self-efficacy of the respondents to compliance with glaucoma 
treatments: 
Table (5.4.5), represents the participants total agreement level related to their perception  
of self-efficacy with a mean (M=2.99). The statement that had the highest  
mean(M=3.11) was "There are things I can do to prevent my glaucoma from getting 
worse", that mean 62.2% of the participants  know that. Then the statement " There are 
things I can do to control my glaucoma" with mean (M=3.00), that mean 60% of the 
participants  know that. While the statement that had the lowest mean (M=2.99) was " I 
can place the eye drops into my eye correctly without any assistance ", that mean  
59.8% of the participants  know that. 
 
 Barriers to compliance Mean Std Agreement 
level with 
sentence 
28 Sometimes the drops aren‘t with me when 
it is time to take them. 
3.34 1.34 moderate 
26 Sometimes I forget to use my drops. 3.26 1.42 moderate 
30 My eye drops are  reasonably priced 3.23 1.41 moderate 
29 Sometimes the drops are painful or 
uncomfortable to take. 
3.10 1.33 moderate 
33 My eye drops cause me no  pain or 
discomfort. 
3.08 1.32 moderate 
32 Sometimes I am out of drops. 3.05 1.38 moderate 
27 Sometimes I fall asleep before dosing time 3.02 1.43 moderate 
31 I suffer from side effects when using my 
drops. 
2.76 1.34 moderate 
 Total agreement level related to their 
perception of treatments barriers 
3.11 .77 moderate 
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Table 5.4.5: Represent the participant (glaucoma patients) self efficacy  
 
 
5.4.6: Perception of the Cause-to-action to compliance with glaucoma 
treatments: 
The respondents total agreement level related to their perception  of cues-to-action  was 
moderate with a mean (M=2.95). The statement that had the highest mean (M=3.10)  
was  "A friend or family member‘s experience with eye drops has encouraged me to use 
my eye drop",  that mean 62% of the participants  know that. Then the statement "I use 
reminders to help me remember to take my eye drop medications" with mean (M=2.79), 
that mean 55.8% of the participants  know that. As table (5.4.6) shows. 
 
 
 
 
 
Self-efficacy Mean Std Agreement 
level with 
sentence 
40 There are things I can do to prevent my 
glaucoma from getting worse. 
3.11 1.09 Moderate 
39 There are things I can do to control my 
glaucoma. 
3.00 .97 Moderate 
36 My eye drops are difficult  to use. 2.75 1.34 Moderate 
38 I will always use my eye drops every day. 3.33 1.20 Moderate 
35 I need assistance putting  drops in my eyes. 2.98 1.29 Moderate 
34 I have a great deal of difficulty putting in my 
eye drops. 
2.78 1.31 Moderate 
37 I can place the eye drops into my eye correctly 
without any assistance. 
2.99 1.26 Moderate 
 Total agreement level related to their perception  
of the self-efficacy 
2.99 .62 Moderate 
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Table 5.4.6: Represent  results of Cause-to-action to compliance with glaucoma 
treatments : 
 
 
5.4.7: Self report of compliance with glaucoma treatments: 
 
Table (5.4.7), represents the participants Total agreement level related to their 
perception  of  Self-report of compliance with a mean (M=3.52). The statement that had 
the highest mean (M=3.58) was "Do you use your eye drops daily", that mean 70.4% of 
the participants  know that. Then the statement " Over the last month I have not missed 
taking my eye drops" with mean (M= 3.45), that mean 69% of the participants  know 
that. 
 
Table 5.4.7: Represents results of Self report of compliance with glaucoma treatments: 
 
 
 Cues-to- action Mean Std Agreement 
level with 
sentence 
42 A friend or family member‘s experience with eye 
drops has encouraged me to use my eye drops. 
3.10 1.24 Moderate 
41 I use reminders to help me remember to take my 
eye drop medications. 
2.79 1.18 Moderate 
 Total agreement level related to their perception  
of cues-to-action 
2.95 .97 Moderate 
 Self-report mean Std Agreement 
level with 
sentence 
43 Do you use your eye drops daily  3.58 1.20 Agree 
44 Over the last month I have not missed taking my 
eye drops 
3.45 1.24 Agree 
 Total agreement level related to their perception  
of  Self-report 
3.52 1.11 Agree 
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5.4.8: Patients physician relationship: 
what is the Patient –physician relationship? To answer this question means and standard 
deviation of items were calculated. As table (5.4.8) shows that the participants total 
agreement level related to their perception  of patient-physician relationship with a 
mean (M=3.32). The statement that had the highest mean (M=3.76)  was" I completely 
agree with my  doctor‘s diagnosis of glaucoma in my eye(s). ", that mean 75.2% of the 
participants  know that. Then the statement" I am happy with the care I  get from my 
eye doctor(explain every things about the disease, it's treatments ,and the best way to 
use eye drops) " with mean (M=3.70), that mean 74% of the participants  know that. 
While the statement that had the lowest mean (M=2.51) was " My doctor does not listen 
to  me ", that mean 50.2 % of the participants  know that. 
 
Table 5.4.8: Represent results of patients physician relationship: 
 
 
 
 
 
 
 
 Related to patient-physician relationship Mean Std Agreement 
level with 
sentence 
45 I completely agree with my  doctor‘s diagnosis of 
glaucoma in my eye(s). 
3.76 1.04 Agree 
47 I am happy with the care I  get from my eye 
doctor(explain every things about the disease, it's 
treatments ,and the best way to use eye drops) 
3.70 1.14 Agree 
46 My doctor does not listen to  me. 2.51 1.29 Moderate  
 Total agreement level related to their perception  
of patient-physician relationship 
3.32 .49 Moderate 
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5.4.9: Differences between the level of knowledge about glaucoma, and 
the demographic characteristics: 
 
To show if there is a relation between the level of glaucoma patient‘s knowledge and 
demographic variables, a hypothesis stated that:  
 
There are significant differences at level of significant α ≤ 0. 05 in the degree of 
knowledge level, and demographic variables, (age, address, marital status, educational 
level, occupation, income, health insurance).  
 
To examine the hypothesis one way ANOVA test done to compare means of the degree 
of knowledge level and demographic variables (age, address, marital status, educational 
level, occupation, income, health insurance). As shown in (5.4.9) table. 
Table 5.4.9: Represents the results of knowledge about glaucoma, and the demographic 
variable: 
Variable Group Mean Std F value  Sig.  
Age group 20-30 3.22 0.34 .270 .929 
31-40 3.29 0.41 
41-50 3.26 0.30 
51-60 3.22 0.38 
61-70 3.26 0.32 
71-80 3.23 0.36 
A dress City 3.26 .38 .255 .775 
Rural area          3.23 .31 
Camp 3.24 .37 
Marital 
status 
Single 3.24 .35 .686 .561 
Married 3.26 .37 
Divorced 3.13 .34 
Widowed 3.26 .30 
Educational 
level 
Illiterate 3.20 .33 2.003 .078 
 
 
 
 
 
 
 
 
 
Primary 
School 
3.19 .31 
Secondary 
School 
3.23 .42 
Diploma 3.30 .31 
BA degree 3.33 .35 
Master 
degree 
3.45 .26 
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Work 
status 
Employed 
/labor 
3.22 .39 1.140 .338 
Retired 3.18 .34 
House wives 3.32 .35 
Unemployed 3.24 .31 
Other 3.24 .39 
Income 1500-2499 
NIS 
3.22 .38 .994 .411 
2500-
3499NIS 
3.28 .35 
3500-
4499NIS 
3.21 .31 
4500-
5499NIS 
3.36 .32 
5500 and 
more 
3.22 .34 
Health 
insurance 
Yes 3.25 .35 .001 .979 
No 3.25 .38 
 
There was no significant differences at level of significant α ≤ 0. 05 in the degree of 
knowledge level and demographic variables (age, address, marital status, occupation, 
income,  health insurance) as shown in (5.4.9) table. 
5.4.10: Relationships between compliance and (dropper difficulties,  
physical inability, and side effects of topical treatment: 
 
To study if there is a relationship between compliance level and dropper difficulties, 
physical inability, and side effects of topical treatment, a hypothesis stated that: 
There is significant correlation  at level of significant α ≤ 0. 05 in the degree of 
compliance with the dropper difficulties, physical inability, and side effects of 
medication. 
To  test the hypothesis Pearson correlation coefficient was calculated in  (5.4.10) table.  
Table 5.4.10: Represent the results of Pearson correlation coefficient:   
    dropper difficulties, physical inability, 
and side effects of medication 
Degree of 
Compliance 
Pearson 
Correlation 
.505 
Sig. (2-tailed) .000 
N 320 
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The result shows that there was a positive significant correlation at level of significant α  
≤ 0. 05 in the degree of compliance with dropper difficulties, physical inability of 
glaucoma patients, and side effects with (Pearson Correlation 0.505). 
 
5.4.11: Relationships between compliance and medication numbers 
and frequency of using drops: 
 
To study if there was a relationship between compliance and medication numbers and 
frequency of using drops, a hypothesis stated that:   
There are significant differences at level of significant α ≤ 0. 05 in the degree of 
compliance with anti-glaucoma medication with respect to medication  numbers and 
frequency of drops. 
To examine the hypothesis chi-square test used to test the relation of compliance and 
medication numbers and frequency of using drops as show in (5.4.11) table. 
 
Table 5.4.11: Results of Chi-Square Test for Significance of medication number and 
frequency  of using eye drops on compliance. 
 Compliance group    
Noncompliance compliance    
No. Percent No Percent 
Chi-
square 
Sig. sig. 
or 
not 
sig. 
Number of eye 
glaucoma 
medications 
prescribed 
One 59 18% 15 5% 6.903 
  
  
.032 
  
  
sig. 
  
  
Two 83 26% 47 15% 
three and more 87 27% 29 9% 
Frequency of 
using eye drops 
One 34 11% 8 3% 5.746 
  
  
.057 
  
  
not 
sig. 
  
  
Two 103 32% 54 17% 
three and more 92 29% 29 9% 
 
There was significant correlation at the level of significant α ≤ 0.05 between compliance 
and number of eye glaucoma medication prescribed where increase number of eye 
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glaucoma medication prescribed increase the noncompliance level. While the frequency 
of using eye drops had no significant correlation with treatment compliance level.  
5.4.12: Relationships between compliance and having medical 
insurance:  
To test if there is a relationship between compliance and having medical insurance, 
hypothesis stated that: 
There is significant differences at level of significant α ≤ 0. 05 in the degree of barriers 
that glaucoma patients  faced when compliance to topical glaucoma with respect to 
having medical insurance. 
To examine the hypothesis chi-square test used to test the relation between degree of 
compliance and barriers that glaucoma patients faced related to having medical 
insurance as shown in (5.4.12) table. 
Table 5.4.12: Represents the results of chi-square test related to  Relationships between 
compliance and medical insurance:  
 Compliance group       
Noncompliance compliance       
No. Percent No. Percent Chi-
square 
Sig. sig. 
or 
not 
sig. 
Is there 
health 
insurance 
for the 
family 
Yes  182 57% 74 23% .138 
  
.710 
  
not 
sig. 
  
No 47 15% 17 5% 
What is the 
type of the 
insurance 
Public insurance 96 38% 41 16% .766 
  
  
  
.858 
  
  
  
not 
sig. 
  
  
  
Private insurance 26 10% 12 5% 
UNRWA insurance 46 18% 15 6% 
Other 14 5% 6 2% 
Does family 
insurance 
cover the 
cost of  
glaucoma 
checkup and 
treatments? 
High  percentage  around 
75% of the total cost    
7 2% 6 2% 2.521 
  
  
  
  
.536 
  
  
  
  
not 
sig. 
  
  
  
  
Moderate percentage 
around 50% of the total 
cost        
31 12% 12 5% 
Low percentage around 
25% of total the  cost    
29 11% 15 6% 
Doesn‘t cover  93 36% 40 16% 
I don‘t know 17 7% 6 2% 
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There was no significant differences at level of significant α  ≤ 0. 05 in the degree of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to having medical insurance, because  their insurance didn‘t cover the cost of follow up 
and treatment.   
 
  
5.4.13: Compliance degree with respect to age and gender: 
 
To see if there is a differences in the degree of compliance with respect to age and 
gender, a hypothesis stated that:  
There is significant differences at level of significant α ≤ 0. 05 in the degree of barriers 
that glaucoma patients faced when compliance to topical glaucoma with respect to age 
and gender. 
To examine the hypothesis chi-square test used to test the relation between the degree of 
compliance with topical glaucoma treatment with respect to age and gender. As shown 
in  table (5.4.13). 
Table 5.4.13: Chi-square test results of compliance degree with respect to age and 
gender:  
 Compliance group       
Noncompliance Compliance       
No. Percent No. percent Chi-
square 
Sig. sig. 
or not 
sig. 
Gender Male 131 41% 47 15% .815 
  
.367 
  
not 
sig. 
  
Female 98 31% 44 14% 
Age group 20-30 31 10% 10 3% 2.605 
  
  
  
  
  
.761 
  
  
  
  
  
not 
sig. 
  
  
  
  
  
31-40 33 10% 17 5% 
41-50 33 10% 14 4% 
51-60 43 13% 21 7% 
61-70 56 18% 18 6% 
71-80 33 10% 11 3% 
 
There was no  significant differences at level of significant α  ≤ 0. 05 in the degree    of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to age and gender. 
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 5.4.14: Compliance degree with respect to their address: 
 
To see if there is a differences in the degree of compliance with respect to their address,  
a hypothesis stated that: 
There is significant differences at level of significant α  ≤ 0. 05 in the degree of barriers 
that glaucoma patients faced when compliance to topical glaucoma with respect to their 
address. 
To examine the hypothesis chi-square test used to test the relation between degree of 
compliance with topical glaucoma treatment with respect to their address. As shown in 
(5.4.14) table. 
 
 
Table 5.4.14: Represent results of compliance degree with respect to address: 
 
 Compliance group       
noncompliance Compliance       
No. percent No. Perce
nt 
Chi-
square 
Sig. sig. 
or not 
sig. 
Address \ 
location 
City 89 28% 35 11% .064 
  
  
.96
9 
  
  
not 
sig. 
  
  
Rural area          95 30% 39 12% 
Camp 45 14% 17 5% 
 
There was no significant differences at level of significant α  ≤ 0. 05 in the degree of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to their address. 
 
5.4.15: Compliance degree with respect to their  marital status: 
 
To see if there is a differences in the degree of compliance with respect to Their marital 
status, a hypothesis stated that: 
 
There is significant differences at level of significant α ≤ 0. 05 in the degree of barriers 
that glaucoma patients faced when compliance to topical glaucoma with respect to their 
marital status. 
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To examine the hypothesis chi-square test used to test the relation between degree of 
compliance with topical glaucoma treatment with respect to marital status as shown in 
(5.4.15) table. 
 
Table 5.4.15: Represent the results of compliance degree with respect to marital status: 
 
Compliance group       
noncompliance Compliance       
No. Percent No. 
Perce
nt 
Chi-
square 
Sig. sig. 
or not 
sig. 
Marital  status Single 39 12% 12 4% 3.288 
  
  
  
.349 
  
  
  
not 
sig. 
  
  
  
Married 130 41% 64 20% 
Divorced 11 3% 7 2% 
Widowed 43 13% 14 4% 
 
There was no significant differences at level of significant α  ≤ 0. 05 in the degree of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to their marital status. 
 
5.4.16: Compliance degree with respect to their educational level: 
 
To see if there is a differences in the degree of compliance with respect to their 
educational level, a hypothesis stated that: 
 
There is significant differences at level of significant α ≤ 0. 05 in degree of barriers that 
glaucoma patients faced when compliance to topical glaucoma with respect to their 
educational level 
To examine the hypothesis chi-square test used to test the relation between the degree of 
compliance with topical glaucoma treatment with respect to their educational level. as 
shown in the (5.4.16) table. 
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Table 5.4.16: Represent the Compliance degree with respect to their educational level: 
 Compliance group       
noncompliance Compliance       
No. percent No. Percent Chi-
square 
Sig. sig. 
or not 
sig. 
Educational 
level 
Illiterate 28 9% 9 3% 6.260 
  
  
  
  
  
.100 
  
  
  
  
  
not 
sig. 
  
  
  
  
  
Primary 
School 
74 23% 22 7% 
Secondary 
School 
58 18% 19 6% 
After School 
Education 
(Diploma, 
BA, and 
Master 
degree) 
67 21% 43 13% 
 
There was no significant differences at level of significant α  ≤ 0. 05 in the degree of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to their educational level. 
 
5.4.17: Relationships between compliance and level of glaucoma 
patient vision: 
 
There is significant differences at level of significant α  ≤ 0. 05 in the degree of barriers 
that glaucoma patients faced when compliance to topical glaucoma with respect to their 
level of vision. 
To examine the hypothesis chi-square test used to test the relation between degree of 
compliance with topical glaucoma treatment with respect to their vision, as shown in 
table (5.4.17).  
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Table 5.4.17: Represent the results of compliance degree with respect to their vision:  
 Compliance group       
Noncompliance Compliance       
No. Percent No. Percent Chi-
square 
Sig. sig. 
or 
not 
sig. 
vision 
group 
Normal 100 31% 45 14% 2.927 
  
  
.231 
  
  
not 
sig. 
  
  
low vision 68 21% 30 9% 
Blindness 61 19% 16 5% 
 
There was no significant differences at level of significant α  ≤ 0.05 in the degree of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to their level of vision. 
5.4.18: Relation of other independent variables on compliance: 
To see the relation of past glaucoma family history, systemic co morbidity such as 
hypertension, diabetes, and ischemic heart disease, whose refer glaucoma patient to 
SJEHG,  duration of the disease,  availability of transportation to SJEHG, work status,  
and household income I used Chi-square test to test the dependence of compliance and 
these variables as shown in table (5.4.18). 
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Table 5.4.18: Represent the results of Chi-square test about relation between 
compliance and family history, comorbidity, referral physician, date of diagnosing, 
availability of transportation to SJEHG, work status,  and household income as 
independent variables: 
 Compliance group       
Noncompliance Compliance       
No. Percent No. Percent Chi-
square 
Sig. sig. 
or 
not 
sig. 
Is there past family 
history of glaucoma? 
Yes 65 20% 32 10% 1.417 
  
.234 
  
not 
sig. 
  
No 164 51% 59 18% 
Do you have any 
systemic comorbidity 
such as hypertension, 
diabetes, and ischemic 
heart   disease? 
Yes 128 40% 48 15% .261 
  
.610 
  
not 
sig. 
  
No 101 32% 43 13% 
No 38 12% 7 2% 
Whose refer you to 
SJEHG ? 
Governmental 
Hospital 
86 27% 45 14% 6.734 0.034 Sig. 
  
  
  
  
Private 
Ophthalmic 
Clinic 
24 8% 5 2% 
 Self Referral 103 32% 47 15% 
Date first diagnosed in 
years  
one to five 105 33% 36 11% 1.786 
  
  
  
  
.775 
  
  
  
  
not 
sig. 
  
  
  
  
six to ten 59 18% 24 8% 
eleven to 
fifteen 
19 6% 11 3% 
sixteen to 
twenty 
27 8% 11 3% 
more than 20  19 6% 9 3% 
Is transportation and 
access available 
between the place of 
residence and SJEHG 
which offers follow up 
for glaucoma patients? 
Yes 191 60% 84 26% 4.270 
  
.039 
  
Sig 
 
 
 
 
 
 
 
No 38 12% 7 2% 
 
Household Income 
2500-3499NIS 76 24% 20 6% 7.807 .099 
not 
sig. 
  
3500-4499NIS 81 25% 43 13% 
 
4500-5499NIS 38 12% 11 3% 
5500 and more 9 3% 7 2% 
5500 and more 25 8% 10 3% 
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Work status Employed 
/labor 
68 21% 37 12% 6.442 .169 
  
not 
sig. 
Retired 21 7% 6 2% 
 
House wives 48 15% 25 8% 
Unemployed 81 25% 21 7% 
Other 7 2% 6 2% 
 
There was  no significant differences at level of significant α  ≤ 0. 05 in the degree of 
barriers that glaucoma patients faced when compliance to topical glaucoma with respect 
to past family history of glaucoma, systemic co-morbidity such as hypertension, 
diabetes, and ischemic heart disease, duration of the disease, work status, and household 
income. 
While transportation, and whose refer glaucoma patient to SJEHG, had significant 
effect on compliance to topical anti-glaucoma treatments as shown in previous table 
(5.4.18), with (P value=0.039) and (P value=0.034) respectively. 
5.4.19: Relation between degree of compliance and two most recent 
intra-ocular pressure: 
To see if there is a relation between degree of compliance and two most recent intra-
ocular pressure, a hypothesis stated that: 
There is significant correlation at the level of significant α ≤ 0.05 between degree of 
compliance and Two most recent intra-ocular pressure results (Right Eye, Left Eye ) 
Previous visit and Current visit. 
To test the hypothesis Pearson Correlation Coefficient calculated in table (5.4.19). 
Table 5.4.19: Represent the results of person correlation test about the relation of two 
most recent intra-ocular pressure and degree of compliance.  
Correlations 
  
Total 
 Right Eye 
(Previous 
visit) 
Left Eye 
(Previous 
visit) 
Right Eye 
(Current 
visit ) 
Left Eye 
(Current 
visit ) 
compliance Pearson 
Correlation 
1 .067 -.003 -.012 -.009 
Sig. (2-
tailed) 
  
.233 .959 .828 .874 
N 320 320 318 319 320 
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There was no significant correlation at the level of significant α ≤ 0.05 between degree 
of compliance and two most recent intra-ocular pressure results (Right Eye, Left Eye) 
Previous visit and Current visit related to study time. 
 
5.5.1: Relationship between the independent variables as categories 
and degree of compliance:  
In this section I tried to find which one of the independent variables  (perception of 
knowledge about glaucoma, perception of benefits, perception of severity, perception of 
susceptibility, perception of barriers,  perception of self efficacy, perception of cause to 
action, perception of self report compliance, perception of patients physician 
relationship)  had the most significant effects on the degree of compliance, a hypothesis 
stated that:  
There is no significant correlation at the level of significance α ≤ 0.05 between degree 
of compliance and  factors (knowledge, benefits, severity, susceptibility, barriers, self-
efficacy, cues-to-action, self-report, patient-physician relationship. 
To test the hypothesis the" Multiple Linear Regression" used to fined orders of the 
factors related to their affect on the degree of compliance (stepwise regression used) as 
shown in table (5.5.1). The most significant factors affect the degree of compliance were 
knowledge, then self efficacy, then treatment barriers, then susceptibility, then self 
report ,then disease severity, then  benefits of using treatments, then cues to action, 
finally patient physician relationship. 
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Table 5.5.1: Represent the relationship between the independent variables (perception of 
knowledge about glaucoma, perception of benefits, perception of severity, perception of 
susceptibility, perception of barriers,  perception of self efficacy, perception of cause to 
action, perception of self report compliance, perception of patients physician 
relationship) and degree of compliance:  
 
Model Summary 
Model R R Square Adjusted 
R Square 
Std. Error of 
the Estimate 
dimension0 1 .642
a
 .413 .411 .18991 
2 .839
b
 .704 .702 .13493 
3 .885
c
 .782 .780 .11595 
4 .915
d
 .838 .836 .10022 
5 .942
e
 .888 .886 .08353 
6 .970
f
 .940 .939 .06093 
7 .982
g
 .965 .964 .04698 
8 .993
h
 .986 .986 .02920 
9 1.000
i
 1.000 1.000 .00000 
a. Predictors: (Constant), knowledge 
b. Predictors: (Constant), knowledge, self efficacy 
c. Predictors: (Constant), knowledge, self efficacy, barriers 
d. Predictors: (Constant), knowledge, self efficacy, barriers, susceptibility 
e. Predictors: (Constant), knowledge, self efficacy, barriers, susceptibility, self report 
f. Predictors: (Constant), knowledge, self efficacy, barriers, susceptibility, self report, 
severity 
g. Predictors: (Constant), knowledge, self efficacy, barriers, susceptibility, self report, 
severity, benefits 
h. Predictors: (Constant), knowledge, self efficacy, barriers, susceptibility, self report, 
severity, benefits, cues to action 
i. Predictors: (Constant), knowledge, self efficacy, barriers, susceptibility, self report, 
severity, benefits, cues to action, patient physician 
 
5.5.2: Relationships between the independent variables knowledge  and 
degree of compliance:  
 
To examine which variable of knowledge has the most effects on compliance, 
 a hypothesis stated that: 
There is no significant of correlation at the level of significant α ≤ 0.05 between degree 
of compliance and factors of (knowledge). 
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To test the hypothesis the "Multiple Linear Regression" used to fined factors that most 
affect the degree of compliance (stepwise regression used), as shown in table (5.5.2), the 
most factors affect the degree of compliance were: being older increases the chances of 
developing glaucoma, then glaucoma can be caused by  an eye injury increase the 
chances of developing glaucoma. 
Table 5.5.2: Represent the most important variable of knowledge affect the degree of 
compliance: 
Model Summary 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
dimension0 1 .465
a
 .216 .213 .21940 
2 .529
b
 .279 .275 .21064 
3 .585
c
 .342 .336 .20165 
4 .609
d
 .370 .362 .19754 
5 .635
e
 .403 .393 .19272 
6 .661
f
 .437 .426 .18736 
7 .676
g
 .457 .445 .18436 
8 .691
h
 .477 .464 .18111 
9 .703
i
 .494 .479 .17854 
10 .708
j
 .501 .485 .17758 
11 .713
k
 .508 .491 .17657 
a. Predictors: (Constant), a5 
b. Predictors: (Constant), a5, a10 
c. Predictors: (Constant), a5, a10, a3 
d. Predictors: (Constant), a5, a10, a3, a2 
e. Predictors: (Constant), a5, a10, a3, a2, a6 
f. Predictors: (Constant), a5, a10, a3, a2, a6, a12 
g. Predictors: (Constant), a5, a10, a3, a2, a6, a12, a4 
h. Predictors: (Constant), a5, a10, a3, a2, a6, a12, a4, a11 
i. Predictors: (Constant), a5, a10, a3, a2, a6, a12, a4, a11, a7 
j. Predictors: (Constant), a5, a10, a3, a2, a6, a12, a4, a11, a7, a1 
k. Predictors: (Constant), a5, a10, a3, a2, a6, a12, a4, a11, a7, a1, a9 
 
 
5.5.3: Relationships between the independent variables benefit of 
treatments and degree of compliance:  
To examine which variable of treatment benefits has the most affects on compliance,    a 
hypothesis stated that: 
There is no significant of correlation at the level of significant α ≤ 0.05 between degree 
of compliance and factors of (benefits).  
79 
 
To test the hypothesis the "Multiple Linear Regression" used to fined factors that most 
affect the degree of compliance (stepwise regression used) as shown in table (5.5.3), 
factor that had the most affects on the degree of compliance was: major vision loss from 
glaucoma can be prevented with treatment. 
Table 5.5.3: Represent the results of treatment benefits and degree of compliance:  
Model Summary 
Model R R 
Square 
Adjusted 
R Square 
Std. Error of the Estimate 
dimension0 1 .214
a
 .046 .043 .24291 
a. Predictors: (Constant), a13 
 
 
5.5.4: Relationships between the independent variable glaucoma 
severity and degree of compliance:  
To examine which variable of glaucoma severity has the most affects on compliance,  
a hypothesis stated that: 
There is no significant of correlation at the level of significant α ≤ 0.05 between degree 
of compliance and factors of (severity). 
To test the hypothesis the "Multiple Linear Regression" used to fined factors that most 
affect the degree of compliance (stepwise regression used) as shown in table (5.5.4), the 
factor that had the most affect on the degree of compliance were: vision lost totally from 
glaucoma, then the amount of vision lost over the next five years if it will be the same 
as past five it would not effect on their quality of life.   
Table 5.5.4: Represent the results of glaucoma severity and degree of compliance:  
Model Summary 
Model R R Square Adjusted 
R Square 
Std. Error of the 
Estimate 
dimension0 1 .253
a
 .064 .061 .23970 
2 .305
b
 .093 .087 .23637 
a. Predictors: (Constant), b18 
b. Predictors: (Constant), b18, b19 
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5.5.5: Relationships between the independent variables glaucoma 
susceptibility and degree of compliance:  
 
To examine which variable of susceptibility has the most effect on compliance, 
 a hypothesis stated that: 
There is no significant of correlation at the level of significant α ≤ 0.05 between degree 
of compliance and factors of (susceptibility). 
To test the hypothesis the "Multiple Linear Regression" used to fined factors that most 
affect the degree of compliance (stepwise regression used) as shown in table (5.5.5), the 
factor that had the most affects on the degree of compliance was their feeling that they 
are susceptible to blindness more than other people in the same age due to glaucoma 
disease. 
Table 5.5.5: Represent the results of glaucoma susceptibility and degree of compliance:  
Model Summary 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
dimension0 1 .344
a
 .118 .116 .23262 
a. Predictors: (Constant), b23 
 
5.5.6: Relationships between the independent variable treatment 
barriers and degree of compliance:  
 
To examine which variable of treatment barriers has the most affects on compliance,  
a hypothesis stated that: 
There is no significant of correlation at the level of significant α ≤ 0.05 between degree 
of compliance and factors treatment barriers. 
To test the hypothesis the "Multiple Linear Regression" used to fined factors that most 
affect the degree of compliance (stepwise regression used), as shown in table (5.5.6), 
factors that had the most affect on the degree of compliance were: primarily: was the 
availability of glaucoma drops with patients at the prescribed the time,  secondly factor 
was the side effects when using their drops, the thirdly factor was the forgetfulness. 
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Table 5.5.6: Represent the results of glaucoma treatment barriers and degree of 
compliance:  
 
Model Summary 
Model R R Square Adjusted R 
Square 
Std. Error of 
the Estimate 
dimension0 1 .490
a
 .240 .238 .21594 
2 .570
b
 .325 .321 .20388 
3 .594
c
 .353 .347 .19996 
4 .604
d
 .365 .357 .19835 
5 .614
e
 .377 .367 .19681 
6 .620
f
 .385 .373 .19585 
a. Predictors: (Constant), c28 
b. Predictors: (Constant), c28, c31 
c. Predictors: (Constant), c28, c31, c26 
d. Predictors: (Constant), c28, c31, c26, c33 
e. Predictors: (Constant), c28, c31, c26, c33, c29 
f. Predictors: (Constant), c28, c31, c26, c33, c29, c30 
 
 
5.5.7: Relationships between the independent variable glaucoma 
patient self-efficacy and degree of compliance:  
 
To examine which variable of glaucoma patient‘s self-efficacy has the most affects on 
compliance, a hypothesis stated that: 
There is no significant of correlation at the level of significant α ≤ 0.05 between degree 
of compliance and factors of glaucoma patient self-efficacy. 
To test the hypothesis the "Multiple Linear Regression" used to fined factors that most 
affect the degree of compliance (stepwise regression used) as shown in table (5.5.7), 
factors that had the most affect on the degree of compliance were: that glaucoma 
patients having  a great deal of difficulty while  putting their eye drops. Then glaucoma 
patient didn‘t know that there are things they can do to prevent their disease from 
getting worse, then the continuity of using eye drop every day need good level of self 
efficacy to be achieved.   
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Table 5.5.7: Represent the results of glaucoma patient self efficacy and degree of 
compliance: 
Model Summary 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
Dimension0 1 .469
a
 .220 .218 .21880 
2 .559
b
 .313 .309 .20570 
3 .584
c
 .341 .334 .20182 
4 .591
d
 .349 .341 .20089 
a. Predictors: (Constant), c34 
b. Predictors: (Constant), c34, c40 
c. Predictors: (Constant), c34, c40, c38 
d. Predictors: (Constant), c34, c40, c38, c36 
 
 
5.5.8: Relationships between the independent variable cause to action 
and degree of compliance:  
To examine which variable of cues to action has the most affects on compliance we put 
a hypothesis stated that: 
There is no significant of correlation at the level of significant α ≤ 0.05 between degree 
of compliance and factors of cues-to-action. 
To test the hypothesis the "Multiple Linear Regression" used to fined factors that most 
affect the degree of compliance (stepwise regression used) as shown in (5.5.8) table 
(5.5.8),  factors that had the most affects on  the degree of compliance were: using 
reminders to help glaucoma patients to remember taking their eye drop, then  previous 
experience of the family member‘s or a friend with eye drops has encouraged them  to 
use their eye drops. 
Table 5.5.8: Represent the results of cues to action and degree of compliance: 
Model Summary 
Model R R Square Adjusted R 
Square 
Std. Error of 
the Estimate 
dimension0 1 .332
a
 .110 .107 .23371 
2 .356
b
 .127 .121 .23189 
a. Predictors: (Constant), d41 
b. Predictors: (Constant), d41, d42 
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5.5.9: Relationships between the independent variable self report and 
degree of compliance:  
 
To examine which variable of self-report has the most effect on compliance,  
a hypothesis stated that: 
There is no significant of correlation at the level of significant α ≤ 0.05 between degree 
of compliance and factors of self-report. 
To test the hypothesis the "Multiple Linear Regression" used to fined factors that most 
affect the degree of compliance (stepwise regression used), as shown in table (5.5.9), 
the factor that had the most affects on the degree of compliance was using  eye drops 
daily which mean lifelong treatment. 
Table 5.5.9: Represent the results of self report and degree of compliance: 
Model Summary 
Model R R Square Adjusted R 
Square 
Std. Error of 
the Estimate 
dimension0 1 .143
a
 .021 .017 .24521 
a. Predictors: (Constant), d43 
 
 
5.5.10: Relationships between the independent variable patient 
physician relationship and degree of compliance:  
 
To examine which variable of patient physician relationship has the most affects on 
compliance, a hypothesis stated that: 
There is no significant of correlation at the level of significant α ≤ 0.05 between degree 
of compliance and  factors patient-physician relationship. 
To test the hypothesis the "Multiple Linear Regression" used to fined factors that most 
affect the degree of compliance (stepwise regression used) as shown in (5.5.10) table. 
Factors that had the most affect on the degree of compliance were: patient acceptance 
that he/she has glaucoma, then good listening from their doctor.  
84 
 
Table 5.5.10: Represent the results of patient physician relationship  and degree of 
compliance: 
Model Summary 
Model R R Square Adjusted 
R Square 
Std. Error of 
the Estimate 
dimension0 1 .148
a
 .022 .019 .24503 
2 .279
b
 .078 .072 .23829 
a. Predictors: (Constant), e45 
b. Predictors: (Constant), e45, e46 
 
5.6: Differences  between  the degree of compliance and variables 
(personal barriers, treatment barriers, health system barriers, disease 
barriers):  
To examine which barrier has the major affects on patient's compliance level, 
a hypothesis stated that: 
There is no significant of correlation at the level of significant α ≤ 0.05 between degree 
of compliance and other variables (personal barriers, treatment barriers, health system 
barriers, disease barriers). 
To test the hypothesis the Multiple Linear Regression used to fined factors that most 
affect the degree of compliance (stepwise regression used), as shown in table (5.6.1), 
The table shows that the personal barriers had the most affects on the degree of 
compliance since it interpret (20.8%) of variation of compliance, then treatment barriers 
which interpret (14.2%) of variation in compliance, while the two variables interpret 
(35%) of variation in the degree of compliance. 
Table 5.6.1: Represent the results of correlation between degree of compliance and 
variables (personal barriers, treatment barriers, health system barriers, disease barriers). 
Model Summary 
Model R R Square Adjusted R 
Square 
Std. Error of 
the Estimate 
dimension0 1 .456
a
 .208 .205 .86416 
2 .592
b
 .350 .346 .78357 
a. Predictors: (Constant), personal barriers 
b. Predictors: (Constant), personal barriers, treatment barriers 
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 Also I did coefficients test to determine the type of relation between the degree of 
compliance and the two barriers which had the most effect on compliance as next table 
(5.6.2) shows, that there was a positive correlation between degree of compliance and 
personal barriers, while negative correlation between treatment barriers and degree of 
compliance.  
 
Table 5.6.2: Represent the relation between the degree of compliance and (personal 
barrier, treatment barrier): 
Coefficients
 a
 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
T Sig. 
B Std. 
Error 
Beta 
1 (Constant) -1.848- .570  -3.241- .001 
personal 
barriers 
1.656 .177 .456 9.338 .000 
2 (Constant) -.937- .528  -1.775- .077 
personal 
barriers 
2.014 .166 .554 12.118 .000 
treatment 
barriers 
-.653- .076 -.391- -8.545- .000 
a. Dependent Variable: compliance 
 
 
5.7: Summary of the Results: 
 
The overall predicted noncompliance level was 71.6%. While self reported 
noncompliance level was only 41.9% which improves that patient usually 
underestimated their noncompliance level.  Noncompliance was found to be higher in 
males than females (74%) to (69%) respectively. Noncompliance level was higher in 
those above fifty years. Divorced glaucoma patients had the highest noncompliance 
level (94%). Retired and unemployed had a noncompliance level (81%) and (79%) 
respectively. Noncompliance level was high in glaucoma patients who were considered 
blind (79%).  
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Compliance was found to be related to the level of education, with the highest 
noncompliance level was in illiterate (76%). Participants generally had a moderate level 
of knowledge about their disease, which together with self efficacy affected compliance 
positively. 
 
Treatment barriers affected compliance negatively. The factors that had the most impact 
on compliance were, primarily: was the availability of glaucoma drops with patients at 
the prescribed the time, secondly: the side effect of glaucoma drops, thirdly: 
forgetfulness.  
Despite the majority of Glaucoma patients having insurance they were noncompliant, 
because their insurance didn‘t cover the cost of follow up and treatment so they paid out 
of pocket.  
 
According to number of eye drop and frequency of using it there was significant 
correlation between compliance and number of eye drops prescribed. While the 
frequency of using eye drops, had no significant correlation with treatment compliance 
level.  
Family history of glaucoma had no significant relation with compliance level, but 
patients with positive family history were compliant more than patients without family 
history of glaucoma (675) and (74%) respectively.  
 
Comorbidity with other systematic disease had no significant relation with compliance 
level, although it was associated with high level of noncompliance (73%). Related to 
disease duration the highest noncompliance level was in the first five year of treatments 
(74%).  Transportation had significant affects on noncompliance level (84%) compared 
(69%). With regard to patient physician relationship it had affects their compliance level 
positively; effective communication with the health care provider and careful listening 
beside spending enough time with patients was the effective factors to improve their 
level of compliance. 
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Chapter Six: 
 
Discussion, Conclusion, and Recommendations:   
 
This chapter aims to discuss the results of this study of  compliance among 
glaucoma patients who attended SJEHG clinic at Jerusalem, Hebron and Anabta. It also 
highlights the results related to the purpose of this study. 
 
Conclusions drawn from the results, and recommendations of what need be done 
in the future to combat noncompliance, as well as recommendation to continue research 
in this field, will also be illustrated. 
 
6.1: Compliance level of glaucoma patients: 
 
Before start talking about  glaucoma noncompliance level and the factors affecting their 
compliance with topical glaucoma treatment at SJEHG, I need to know these facts 
related to the context of the study: Israel‘s continued occupation of the State of 
Palestine is throwing people into poverty and severely impeding sustainable 
development. The State of Palestine‘s delegate stressed that 42% of  Palestinians 
inhabitants are now refugees after 69 years of Israeli occupation. Adding that Israel 
controlled more than 61 per cent of the West Bank, driving Palestinians from their land 
and hindering economic activity. The continuing occupation impedes access to 
resources, opportunities, services and aid, compounding the problems faced by 
Palestinians from all sectors of society. With high unemployment among men and the 
loss of family members to prison or death. Beside the Israeli system of checkpoints, 
roadblocks, and closures, which has separated Palestinians from Israel and Jerusalem 
and made travel between the West Bank and Gaza Strip nearly impossible. Within the 
West Bank, there are over 700 kilometers of roadways that Palestinians need a special 
permit to travel on. Israelis have obstructed roads in hundreds of locations with piles of 
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boulders, cement blocks or trenches to further inhibit movement, cutting off many 
towns and villages from direct vehicular access. There are 60 permanently staffed 
Israeli military checkpoints in the West Bank in addition to ―flying‖ or temporary 
checkpoints. Palestinians require permits from the Israeli authorities to leave their 
villages or towns, which are difficult to obtain. In addition, Palestinians do not enjoy 
independent international borders for trade or travel. Poverty cannot be viewed purely 
as an economic issue. Not only does poverty have many social impacts, economically, 
this translates into a lack of access to markets, raw materials, means of production, job 
opportunities, and labor. The lack of freedom of movement negatively affects access to 
education, mental and physical health services, People are not seeking medical 
treatment unless absolutely necessary because of cost and mobility issues. These 
consequences increase disproportionately for the poor (United Nations Office for the 
Coordination of Humanitarian Affairs,2014). 
 
Noncompliance with medical therapy has long been recognized as an important limiting 
factor in the medical management of any chronic disease. Patients with glaucoma who 
have lower rates of compliance, are presumed to be at greater risk of developing visual 
loss (Stryker et al., 2010). This study was done to a assess compliance level and the 
factors affecting compliance to glaucoma medications among sample of Palestinian 
glaucoma population drown from SJEHG as a developing country under occupation. 
After analysis, results showed, glaucoma patients in this study, had a high percentage of 
noncompliance (71.6%), that frames the magnitude of the problem.  
 
The results of this study was corresponded with Olthoff et al., (2005) study that shows 
noncompliance level (72.7%) in Dutch. And Khandekar et al., (2005) that shows 
noncompliance rate of  75.2% was reported among Oman glaucoma population in 2005. 
 
While a study was done in Egypt by Abu Hussein et al., (2015) shows that 
noncompliance with glaucoma medication is (53.6%). Other studies that reported 
noncompliance level is (55.0–60.0%) in USA (Nordstrom et al., 2005; Sleath et al., 
2006; Tsai, 2009; Okeke et al., 2009). 
  
A study by  Masoud et al., (2013), shows that noncompliance rates in Western 
populations and in the rest of Israel vary from 27.4%  to 42%. 
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6.2: Compliance level of glaucoma patients related to  level of 
knowledge and level of education: 
 
After analysis, results showed, that glaucoma patients in this study had a moderate level 
of knowledge about their disease with a mean (M=3.25), and the high level of 
knowledge were about permanent vision lost from glaucoma with a mean (M=3.81).  
On the opposite side glaucoma patients didn‘t have enough knowledge about glaucoma 
disease if it is always genetic or not,  with a lowest mean (M=2.72). 
Knowledge level about glaucoma disease in this study was the important factor 
affecting their level of compliance positively as multiple linear regression test shows in 
(table 5.5.1). 
This result coincides with Masoud et al., (2013) results about factors associated with 
nonadherence included inadequate knowledge which get a high percent (32%). Lack of 
knowledge and misunderstanding were the main factors cited for the >57% 
noncompliance rates in Arab population in Israel. 
 
This is consistent with Khandekar et al., (2005) study in Oman, that showed better 
knowledge about glaucoma is associated positively with better compliance rates. The 
knowledge about glaucoma was reported to be good in 23.8% of patients, who 
demonstrated higher compliance rates, the study reported that over a third of glaucoma 
patients failed to use their ophthalmic medications properly, mainly due to lack of 
knowledge. 
 
Similarly to a study by Yoo, and Hwang (2015) that reported  higher knowledge about 
glaucoma medication was significantly associated with a higher compliance score (p < 
0.05). 
 
This study didn‘t find significant association between educational level and 
noncompliance. Which could reflect that educational level didn‘t give proper 
knowledge about disease, which leads them to being noncompliant. The highest 
noncompliance level was in the illiterate (76%) and the lowest level was with those with 
master degree (57%). This data is validates other studies like Stryker et al., (2010) done 
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in Egypt, that shows improving knowledge about glaucoma through education 
significantly improved compliance.  
Compared with Abu Hussein et al., (2015) study which reported that patient with low 
level of education were  associated with poor compliance level.  
Similarly, result of Olthoff et al., (2009) study showed that there was no association 
between non-adherence and level of education. 
 
 
6.3: Compliance level of glaucoma patients related to age and gender: 
               
Results of this study found noncompliance common among both sexes, A higher rate of 
noncompliance among males than females (74%)  to (69%) respectively. 
 
This result is similar to study conducted by Abu Hussein et al., (2015) in Egypt, which 
showed males had a tendency for higher noncompliance than females.  
 
This is contrary to Khandekar et al., (2005), study reported that gender per se is not 
associated with increased noncompliance. 
Masoud et al., (2013), did  a study among an Arab population in Israel results revealed 
that general rate of noncompliance, for both genders, was found to be 50%. 
Compared to Olthoff et al., (2009) study results done in Dutch patients found that there 
was no association between non-adherence and sex.  
Similarly a study by Yoo, and Hwang  (2015) was done in Korea reported that sex was 
not significant in compliance score. 
            
Glaucoma patients age had insignificant affects on compliance to topical glaucoma 
treatment. In this study, higher noncompliance level was found in younger and old age 
groups from (20-30) and (61-70), (76%) for each one. Noncompliance level was higher 
in those above fifty years, which fits that older patients may have a lower compliance 
probably due to reduced vision, problems with manual dexterity, coordination, 
comprehension, or memory; however, this was not evaluated in this study. 
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This coincides Sleath et al., (2006) study done in USA found that older patients may 
exhibit poor glaucoma treatment adherence due to difficulty reading prescription labels.  
Masoud, et al (2013) study found that compliance was significantly higher in younger 
patients (age < 50) 63%. Noncompliance was found to be common among an Arab 
population in Israel, particularly between the ages of 50 and 80. 
This is not similar to the study conducted by Tsai, (2009) in USA, that showed older 
age has not been shown to be a consistent risk factor for poor adherence to glaucoma 
medication regimens. Risk factors for poor adherence or nonadherence to topical 
glaucoma medication regimens obstacles are common in the elderly (e.g., reduced 
cognition, musculoskeletal problems, and transportation difficulties). 
Compared with Abu Hussein et al., (2015) study which reported that patient age above 
50 years is associated with poor compliance.  
 
6.4: Compliance level of glaucoma patients related to financial 
coverage (insurance), income, and disease duration: 
 
Another factor that may affect compliance related to this study was financial coverage 
for the cost from their medical insurance. Analysis of the results  showed statistically 
there is no significant differences of barriers that glaucoma patients faced when 
compliance to topical anti glaucoma with respect to having medical insurance as 80% of 
the participant have insurance, because  their insurance didn‘t cover the cost of follow 
up and treatment and they paid out of pocket, which could have been one of the barriers 
that lead to lack of IOP control. This can be related to the economic burden of glaucoma 
medications (eye drops) in Palestine related to their average income level. 
  
This agrees with studies results like, Sleath et al., (2006) ;Tsai (2006) which  found that 
the factors leading to poor compliance were high drug cost. In Egypt a study by Abu 
Hussein et al., (2015) found that Polytherapy and lack of medical insurance could be 
contributing factors for noncompliance in glaucoma patients.  
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Stryker et al., (2010) study that  showed patients with low monthly income were less 
likely to be compliant compared to patients with high monthly income. This finding was 
related to a previous study that revealed unaffordability considerably affects adherence. 
Besides this, patients who purchased ocular hypotensive drops by themselves were less 
likely to be adherent compared to patients who obtained their medications free of 
charge. 
Castel et al., (2014 ) study was done in Haifa and Western Galilee District showed that 
barriers to adherence were found to be low income.  
            
This study found that poor compliance was not associated with disease duration, and the 
highest (74%) level of noncompliance was found in the first five years of using eye 
drops. A study by Parrish et al., (2009) showed that many patients are in denial about 
their health problems, especially in asymptomatic diseases such as glaucoma may this 
explain the high noncompliance level in the first five years of diagnosis. 
This agreed with Olthoff  et al., (2009) study, that found there is  no association 
between non-adherence and duration of disease. It also agreed with a study by Yoo, and 
Hwang (2015), which reported that longer duration of treatment was significantly 
associated with a higher compliance score (p < 0.05). 
 
6.5: Compliance level of glaucoma patients related to medication and 
drop application issues: 
  
This study highlighted  the importance of medication numbers as well as the complexity 
of regimen (frequency of using eye drops) on compliance level among glaucoma 
patients. It showed a statistically positive correlation between the degree of compliance 
and dropper difficulties, physical inability, and side effects of medication with (Pearson 
Correlation 0.505). This agrees with Slota et al., (2015) study in USA result that (45%) 
of patients expressed a problem related to medication side effects during their medical 
encounter with their ophthalmologist. 
           
Contrary to Buchan et al., (2007) a study in United Kingdom, found that the frequency 
of instillation eye drops per day did not affect compliance significantly, although that 
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study has shown that a single daily drug dose or combination is associated with better 
compliance rates. 
  
This is consistent with Nordstrom et al., (2005) study in USA results, that showed 
complexity of taking multiple medications for multiple diseases, change in dosing 
schedules and side effects of medications are all well known reasons for nonadherence, 
complicate their medication adherence, if they have no external help. Once-a-day 
dosing with prostaglandin and beta-blockers have a better persistency. 
 
Similarly to a study by Castel et al., (2014) in Haifa and Western Galilee reported that 
taking a higher number of drops per day, and taking a prostaglandin drug are considered 
a barrier to compliance in glaucoma patients due the side effects. 
  
A study by Gupta et al., (2012) in India showed that when the eye drop application 
techniques were assessed, nine out of ten were unable to instill their eye drops correctly. 
While forgetfulness was the number one reported reason for non-compliance in Taylor's 
(2002) study in USA, in this study, forgetfulness was the third cause of noncompliance 
related treatment barriers. Consistent to Olthoff et al., (2009) study results found that 
forgetfulness, unavailability of eye drops and difficulties with holding the bottle above 
the eye when applying the eye drops, were the most cited reasons for non-adherence,  
and fifty percent of the patients indicated that they required more information on the 
correct administration of eye drops  
Compared with Stryker  et al., (2010) study in USA result, non-adherent participants 
were more likely to have difficulty remembering to take their medications and to 
believe their glaucoma would affect their eye sight in the future.  
 
Similarly a study by Yoo, and Hwang (2015) reported that the most common reason for 
missing medication was forgetfulness (80.5%) related to treatment barriers.  
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6.6: Compliance level of glaucoma patients related to barriers as 
categories: 
 
 In this study the researcher used four major categories which had effect on compliance 
level of glaucoma patients (personal related barriers, treatment related barriers, health 
provider related barriers, and glaucoma related barriers). 
 
This study found that personal related barriers had the most effect on the degree of 
compliance since it interpret 20.8% of variation of compliance, then treatment related 
barriers which interpret 14.2% of variation in compliance, and the other categories' 
didn‘t have much effect on degree of compliance. This results agreed with Sleath et al., 
(2006) study that showed non-adherent glaucoma patients are more likely to have 
impaired visual acuity or partial vision loss which related to personal barrier.  
 
This study found that health provider related barriers affected compliance, in that, 
glaucoma patients who reported that their ophthalmic doctor had not adequately 
explained their eye condition, management and risks, were more likely to be 
noncompliant with using their antiglaucoma medicine. 
 
This is consistent with Taylor et al., (2002) study that showed adherence is better 
achieved where physician take proactive role in discussing with patient regarding their 
disease and use of medication. Communication between physicians and patients is a key 
factor in compliance for glaucoma patients.  
 
Agreed with Kelly  et al., (2009) study reported that communication is an important 
factor over which physicians have some control in helping their patients to adhere. The 
patient-physician interaction remains a cornerstone in improving compliance rates due 
to intolerance. Additionally, the physician must be aware of possible side effects and 
keenly seek them out, while always discussing various treatment options. 
 
The psychometrics of the GTCAT have been studied and modified over the last few 
years, where now it is generally accepted that this instrument shows excellent 
repeatability, content, construct, and predictive validity for glaucoma adherence; and is 
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widely used. Our conclusion concurred that is was a useful and reliable tool, to study 
compliance in Palestinian patients with glaucoma, and served the objectives of the study 
effectively. 
 
6.7: Conclusion and Recommendations: 
          
The results of the current study about glaucoma patients treated at SJEHG  in three 
cities (Jerusalem, Hebron, and Anabta), revealed high level of noncompliance among 
Palestinian glaucoma patients at SJEHG, compared to other studies in developed world. 
Compliance is mostly a multifactorial problem. Higher level of knowledge and patient 
self efficacy were the main positive associations with good level of compliance. Poor 
understanding of the disease may lead to poor compliance. This is a global problem that 
needs cooperation of physicians, media, and social care providers. Extra effort needs to 
be done by health care providers since "the personal related barriers were important 
factors"  to educate our patients about the nature of glaucoma, glaucoma susceptibility, 
importance of treatment, follow-up visits, and effect of treatment on prognosis. Longer 
time has to be spent with our patients teaching them how to instill their drops. Also, 
simplifying treatment regimen and tailoring it to their daily routine lifestyle are a must. 
Reminders of follow-up visits with proper tracking of our patients must be added to our 
health care system. Patients appeared to need sufficient initial information, long-term 
education (with feedback), and the establishment of sufficient medication-faith to 
enable self-management.  
Greater adherence leads to better outcomes, finding ways of addressing the major issue 
of non-adherence is a significant challenge in the care of patients with glaucoma, but 
one with tremendous potential to make a difference. 
 
 The following "Recommendations" will help the management of glaucoma 
and compliance: 
 
This quantitative analysis and comparison of compliant and noncompliant glaucoma 
patients related to topical treatment barriers, has implications for healthcare policy as 
the aging population increases and as treatment adherence potentially becomes an 
increasingly challenging and costly problem. This research also provides important 
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information to guide the development of interventions to improve glaucoma treatment 
adherence.  
 
 Ophthalmologists should spend more time with patients on medical therapy and 
repeatedly explain, among other things, the nature and natural history of the 
disease, the importance of treatment and exactly how they should use their 
drugs. Also encourage nurses to be involved like offering specialization of 
glaucoma nurse practitioner.  
 
 Educating patients about their disease and its complications, using guiding 
brochures and DVDs, and improving the patient-physician relationship by 
personalizing the treatment can plausibly improve compliance rates. 
Furthermore, patients‘ needs and knowledge should be taken into consideration 
in order to improve patients‘ compliances, this is beside using of telephone call 
as a reminder to enhance their level of compliance. 
 
 Glaucoma patients could be taught effective application techniques, inducing 
confidence. Memory aids/cues and the importance of routine could be discussed 
and administration schedules devised so that effective measures to ensure 
adherence are in place at commencement of treatment. 
 
 Health education campaigns concerning glaucoma should be delivered through 
the mediums of radio, television, posters, and pamphlets. It is necessary to target 
patients and the community at large, especially family and friends of glaucoma 
patients. The health education massage could be conveyed by people who 
developed complication as results of non-compliance. 
 
 Government should provide free or highly subsidized drugs for those of them 
that cannot afford to buy their drugs or pay for filtration surgery. 
 
 Future research should focus on assessing the value of health behavior models in 
improving glaucoma medication compliance. The prevalence rate of glaucoma 
and it complications, such a survey would provide useful information for policy 
makers to evaluate medical situation and economic implications with 
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cooperation of focus group in order to help in the formulation of policies related 
this topic. Also we need more qualitative research to obtain more detailed 
information about factors that could improve compliance.    
 
6.8: Limitations: 
 
The following limitations should be considered when interpreting the results of the 
present study.  
 
We limited respondents to those between 20 and 80 years of age. Our sample was not 
representative of all glaucoma patients. Our sample was drawn from SJEHG. This was a 
representative sample from glaucoma specialty care clinics in the SJEHG in three cities, 
and the results may not be representative of patients followed in comprehensive 
ophthalmology clinics elsewhere. Though all patients in the waiting room of the 
glaucoma clinics were approached and asked to complete a survey about how they use 
their glaucoma medications. 
 
The other difficulties I faced were the lack of a national register or database on 
glaucoma patients in Palestine and the dearth of studies on this topic, both regionally 
and in the Palestinian territories; there was some limited data on Arab Israelis. 
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 .egaugnal cibarA ni eriannoitseuQ :B xennA
 
 
 
 
 السيدات و السادة مرضى ضغط العين (جموكوما) <
استكمالا لمتطمبات الحصول عمى درجة الماجستير في الصحة العامة من جامعة القدس.أقوم أنا الباحثة ختام الحسنات بعمل           
 التي تؤثر في التزام مرضى ارتفاع ضغط العين (الجموكوما) باستخدام العلاج بالقطرات" .ىذه الدراسة بعنوان " العوامل 
حيث أن الدراسة تيدف إلى معرفة الأسباب والمعوقات التي تؤثر عمى التزام المرضى الذين تم تشخيصيم بمرض الجموكوما           
 وبالتالي الحفاظ عل النظر. بالقطرات، والتي تعتبر عامًلا مساعدًا في ضبط ضغط العين ، 
الفئة المستيدفة لمدراسة، ىم المرضى المشخصين بمرض ارتفاع ضغط العين (جموكوما) الذين يراجعون العيادات الخارجية في           
 مستشفى سان جون لمعيون في كل من القدس، والخميل، وعنبتا. 
بتوصيات تيدف إلى رفد السياسات العلاجية والإدارية في مراكز ومستشفيات نسعى من خلال نتائج ىذه الدراسة إلى الخروج           
العيون التي ُتعنى بفحص العيون وتشخيص مرض ارتفاع ضغط العين(جموكوما) وزيادة الالتزام بالعلاج بشكل مبكر وفعال. لذا أرجو  من 
يان، وسيقوم الفريق المساعد بشرح وا  يضاح أي استفسار يرد ) دقيقة،من أجل تعبئة ىذا الاستب24حضرتكم الاىتمام، وتكريس ما معدلو (
 خلال تعبئة الاستبانو .
وسيتم مراعاة السرية الكاممة ، والحرية الكاممة  –المعمومات التي ترد في ىذا الاستبيان لن تستخدم إلا لأغراض البحث العممي           
 كبير في إنجاح ىذه الدراسة ،ولكم جزيل الشكر.في المشاركة أو عدميا ، لكني أطمح لمشاركتكم  ودوركم 
 
 
 
     الباحثة                                                                                                                        
 ختــــام الحسنات                                                                                                                    
 
 :اىَؼيٍ٘بد  اىذَٝ٘غشافٞخ (ٍؼيٍ٘بد  شخظٞخ)
 901
 
 .ٕو  اىَشزشك  فٜ الاعزجٞبُ ثؾبعخ ىَغبػذح فٜ  قشاءح  الاعزجٞبُ؟  1
 .لا2.ّؼٌ                                1 
 . اىؼَش  :   . . . . . . . . . . . . .  ػبٍب 2
 .أّضٚ 2.رمش                 1.  اىغْظ :   3
 أسٍو/أسٍيخ -4ٍطيق/ٍطيقخ       - 3ٍزضٗط/ٍزضٗعخ    -2أػضة /ػضثبء   -1:   .اىؾبىخ  الاعزَبػٞخ4
  :      .   اىزؾظٞو اىؼيَٜ 5
 ) أٍٜ (لا ٝقشا ٗ لا ٝنزت)1
 ) شٖبدح  ٍذسعٞخ  أعبعٜ 2
 ) صبّ٘ٝخ   ػبٍخ3            
 ) دثيً٘  ٍز٘عؾ4            
 ) ثنبى٘سٝ٘ط5            
 ) ٍبعغزٞش  أٗ دمز٘سآ         6            
 ) سثخ ٍْضه 3) ) ٍزقبػذ                2) ٍ٘ظف /ػبٍو                 1ىؼَو / اى٘ظٞفخ      .ا6
 د/ؽذدٛ.................................)غٞش رىل ؽذ5) ثلا ػَو                           4                            
 .   دخو أعشرل اىشٖشٛ ثبىشٞقو :7
 شٞنو  9943 - 0052)  3 شٞنو 9942 - 0051)  2شٞنو          0051)  ٍب دُٗ 1
 شٞنو فأػيٚ 0055)  6 شٞنو         9945 - 0054)  5شٞنو       9944 - 0053)  4
 )  ٍخٌٞ. 3      )  قشٝخ2               )  ٍذْٝخ 1                        ٍنبُ اىغنِ :  .  8
 )  لا 2         )  ّؼٌ 1  . ٕو ٝ٘عذ ىيؼبئيخ ربٍِٞ طؾٜ9
  
 .ئرا مبُ ىيؼبئيخ ربٍِٞ طؾٜ فَب ّ٘ع اىزبٍِٞ أٗ اىغٖخ اىَإٍِ ىذٖٝب ؟ 01
 غٞش رىل.   )4)  ربٍِٞ ٗمبىخ         3)  ربٍِٞ قطبع خبص         2   )  ربٍِٞ ؽنٍٜ٘ 1  
 
 .  ٕو ٝغطٜ ربٍِٞ اىؼبئيخ رنبىٞف اىفؾض ٗ اىؼلاط ىَشع اسرفبع ػغؾ اىؼِٞ (عي٘مٍ٘ب)؟11
 )   لا ٝغطٜ اىفؾض ٗاىؼلاط  4)  ثْغجخ قيٞيخ      3)  ثْغجخ ٍؼزذىخ                 2)  ثْغجخ مجٞشح        1  
 )  لا أػيٌ   5
 ِ  ............................. ثبىغْ٘اد.ٍزٚ مبُ  ربسٝخ  اىزشخٞض  ثؼغؾ  اىؼٞ21
 .ٍب ػذد أدٗٝخ اسرفبع ػغؾ اىؼِٞ (عي٘مٍ٘ب) اىزٜ  رزؼبؽبٕب     31
 .صلاصخ  أٗ أمضش        3.اصِْٞ              2.ٗاؽذ              1
                  طجٞت؟اىزٜ اٗطٚ ثٖب اى.مٌ ػذد  ٍشاد  الاعزخذاً  اىٍٜٞ٘ ىقطشاد اسرفبع ػغؾ اىؼِٞ (عي٘مٍ٘ب) 41
 .صلاس ٍشاد أٗ أمضش3.ٍشرِٞ               2.ٍشح ٗاؽذح          1
 011
 
 .ٕو قَذ ثؼَيٞبد  عشاؽٞخ ىٖب ػلاقخ ثَشع اسرفبع ػغؾ اىؼِٞ (عي٘مٍ٘ب)  خلاه  الأشٖش  اىضلاس الأخٞشح ؟51
 .لا2.ّؼٌ                                               1
 اىؼبئيخ أٛ ربسٝخ ٍشػٜ ىلإطبثخ ثبسرفبع ػغؾ اىؼِٞ (عي٘مٍ٘ب) ؟ .ٕو ٝ٘عذ فٜ61
 .لا2.ّؼٌ                                               1
 أٍشاع اىقيت ؟-اىغنشٛ–.ٕو ٝ٘عذ أٍشاع أخشٙ ٍضو اىؼغؾ 71
 .لا2.ّؼٌ                                                1
 ؼِٞ : اىَشاعؼخ اىغبثقخ ٗاىؾبىٞخ ًٝ٘ عَغ اىَؼيٍ٘بد.آخش  قٞبعِٞ  ىؼغؾ  اى81
 ػغؾ اىؼِٞ اىٞغشٙ ػغؾ اىؼِٞ اىَْٞٚ ربسٝخ اىَشاعؼخ اىَشاعؼخ 
    اىَشاعؼخ اىغبثقخ
    اىَشاعؼخ اىؾبىٞخ
   
ؼل اىظؾٜ .ٕو رز٘فش اىَ٘اطلاد ٗٗعبئو اىْقو ثِٞ عنْل ٗ ٍغزشفٚ عبُ عُ٘ ىيؼُٞ٘ اىَقذً ىخذٍخ اىفؾض ٗ اىَزبثؼخ ى٘ػ91
 ثخظ٘ص ٍشع اسرفبع ػغؾ اىؼِٞ (عي٘مٍ٘ب) ؟
 .لا2.ّؼٌ                                               1
 .02
قشٝت ٍِ اىْظش  ؽذح اىجظش
 )6/21- 6/6( اىطجٞؼٜ
-(ٝشٙ اىؼ٘ء ّظش ٍْخفغ
 )6/81
 لا ٝشٙ اىؼ٘ء اىؼَٚ
    اىؼِٞ اىَْٞٚ
    اىؼِٞ اىٞغشٙ
 
 ٍغزشفٚ عبُ عُ٘ ىيؼُٞ٘؟ .ٍِ قبً ثزؾ٘ٝيل ئىٚ12
 .ٍغزشفٚ ؽنٍٜ٘1
 ٍِ ػٞبدرٔ اىخبطخ.ؽجٞت ػُٞ٘ 2
 .عئذ ٗؽذك/ٛ ىؼَو فؾض ّظش فبمزشفذ ثبىظذفخ ئطبثزل ثَشع اسرفبع ػغؾ اىؼِٞ (عي٘مٍ٘ب).3
 
 
 
 
عبد ٗاىقطشاد ٕزا اىقغٌ ٍِ الاعزجبّٔ ٝؾز٘ٛ ػيٚ ػذد ٍِ الأعئيخ ػِ ٍشع اسرفبع ػغؾ اىؼِٞ ، ٗػِ اىزغشثخ اىشخظٞخ ٍغ اىؼلا
 ٗقٞبط اىَؼشفخ ثبىَشع :
  شذح اىَ٘افقخ. 5ٍ٘افق ،  4ٍؾبٝذ ،  3غٞش ٍ٘افق، 2َٝضو شذح ػذً اىَ٘افقخ ،  1اىشعبء اخزٞبس اىشقٌ اىزٛ ٝز٘افق ٍغ اّغغبٍل ، ؽٞش سقٌ 
 111
 
 قٞبط اىَؼشفخ ثبىَشع ٗ ف٘ائذ  اىؼلاط
غٞش   غٞش ٍ٘افق ثشذح ٍؼشفزل ثبىَشع ٗفبئذح اىؼلاط  
 ٍ٘افق
لا 
 اػشف
ٍ٘افق  ٍ٘افق
 ثشذح
ٍؼشفزٜ اىشخظٞخ ثؼ٘اٍو صٝبدح خطش الإطبثخ ثَشع اسرفبع  1
 ػغؾ اىؼِٞ (عي٘مٍ٘ب)  ٍَزبصح
 5 4 3 2 1
ٍؼشفزٜ  ثأػشاع ٍشع اسرفبع ػغؾ اىؼِٞ (عي٘مٍ٘ب)   2
 ٍَزبصح
 5 4 3 2 1
 5 4 3 2 1 ٍشع اسرفبع ػغؾ  اىؼِٞ (عي٘مٍ٘ب)  أعجبثٔ  ٗساصٞخ دائَب 3
ٍِ اىََنِ أُ ٝنُ٘ اىشخض  ٍظبثب ًثَشع اسرفبع  ػغؾ   4
 اىؼِٞ(عي٘مٍ٘ب)  دُٗ ظٖ٘س أػشاع ػيٞٔ  
 5 4 3 2 1
الأشخبص الأمجش عْب ٍؼشػُ٘ أمضش  ىلإطبثخ ثَشع اسرفبع  5
 ػغؾ اىؼِٞ (عي٘مٍ٘ب)
 5 4 3 2 1
الأىٌ ٕ٘ ٍِ  الأػشاع اىشبئؼخ ىَشع اسرفبع ػغؾ  6
 اىؼِٞ(عي٘مٍ٘ب)
 5 4 3 2 1
ٍشع اسرفبع ػغؾ اىؼِٞ (عي٘مٍ٘ب) َٝنِ رشخٞظٔ ثبىشغٌ  7
 ٍِ ٗع٘د ػغؾ ؽجٞؼٜ ىيؼِٞ
 5 4 3 2 1
فقذاُ اىْظش ّزٞغخ اسرفبع  ػغؾ  اىؼِٞ (عي٘مٍ٘ب) لا َٝنِ  8
 اعزشعبػٔ أٛ أّ دائٌ
 5 4 3 2 1
اىغنشٛ ٍِ اىََنِ أُ  ٝغجت ٍشع اسرفبع ػغؾ اىؼِٞ  9
 (عي٘مٍ٘ب)
 5 4 3 2 1
اىؼِٞ ٍَنِ أُ رغجت ٍشع اسرفبع ػغؾ اىؼِٞ  ئطبثبد 01
 (عي٘مٍ٘ب)
 5 4 3 2 1
اىؼَٚ ىٞظ ّزٞغخ ٍؾزَيخ ىَشع اسرفبع ػغؾ  اىؼِٞ  11
 (عي٘مٍ٘ب)
 5 4 3 2 1
الأعجبة اىَإدٝخ ئىٚ ئطبثخ اىشخض ثَشع اسرفبع ػغؾ   21
 اىؼِٞ (عي٘مٍ٘ب)  غٞش ٍفٍٖ٘خ ثشنو عٞذ
 5 4 3 2 1
ت ٍشع اسرفبع ػغؾ  اىؼِٞ فقذاُ اىْظش اىنيٜ ثغج 31
 (عي٘مٍ٘ب)   َٝنِ ٍْؼٔ ثبىؼلاعبد اىطجٞخ
 5 4 3 2 1
أػزقذ أّٔ ٍِ اىََنِ ثغجت ٍشع اسرفبع ػغؾ  اىؼِٞ  41
مع استخدام أػ٘اً ؽزٚ  01(عي٘مٍ٘ب)  أُ أفقذ ّظشٛ خلاه 
  العلاج بالقطرات
 5 4 3 2 1
ىذٙ قطشاد اىؼِٞ فؼبىخ ىيغٞطشح اىنبٍيخ ػيٚ ػغؾ اىؼِٞ  51
 اىَشػٚ اىَظبثِٞ  ثَشع اسرفبع ػغؾ  اىؼِٞ (عي٘مٍ٘ب)  
 5 4 3 2 1
 ئدساك  اىَشٝغ لاؽزَبىٞخ الإطبثخ ثبىَشع ٗشذرٔ
غٞش ٍ٘افق  ئىٚ أٛ ؽذ ر٘افق ػيٚ اىغَو اىزبىٞخ  
 ثشذح
غٞش  
 ٍ٘افق
لا 
 اػشف
ٍ٘افق  ٍ٘افق
 ثشذح
 5 4 3 2 1 ا ٍغز٘ٙ ئطبثزٜ ثَشع اسرفبع ػغؾ اىؼِٞ (عي٘مٍ٘ب) ىٞظ ؽبد 61
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ىٌ افقذ أٛ ّغجخ ٍِ ّظشٛ ّزٞغخ ىَشع اسرفبع ػغؾ اىؼِٞ  71
 (عي٘مٍ٘ب)
 5 4 3 2 1
ٍَنِ أُ افقذ  ّظشٛ ّزٞغخ ىَشع اسرفبع ػغؾ اىؼِٞ  81
 (عي٘مٍ٘ب) 
 5 4 3 2 1
اػزقذ أّ ٍِ اىََنِ ثغجت ٍشع اسرفبع ػغؾ  اىؼِٞ  91
م  استخدم إذا لأػ٘اً  5(عي٘مٍ٘ب)   أُ افقذ  ّظشٛ خلاه 
 القطرات 
 5 4 3 2 1
ئرا فقذد ّفظ اىنَٞخ ٍِ اىشؤٝخ ػيٚ ٍذٙ اىغْ٘اد اىخَظ  02
اىَقجيخ ٍضو اىغْ٘اد اىخَظ اىَبػٞخ ثغجت ٍشع اسرفبع ػغؾ  
 اىؼِٞ (عي٘مٍ٘ب) فأّ ىٞظ ىٖب أٛ رأصٞش ػيٚ  ؽٞبرٜ
 5 4 3 2 1
اػزقذ أّ ٍِ اىََنِ ثغجت ٍشع اسرفبع ػغؾ  اىؼِٞ  12
إذا لم  استخدم أػ٘اً  01ٍب) أُ افقذ  ّظشٛ خلاه (عي٘م٘
 القطرات
 5 4 3 2 1
ىٌ أرفبعأ ػْذٍب ػشفذ ثاطبثزٜ ثَشع اسرفبع ػغؾ  اىؼِٞ  22
 (عي٘مٍ٘ب) 
 5 4 3 2 1
أّب  ٍؼشع ىيؼَٚ أمضش ٍِ غٞشٛ فٜ ّفظ  اىَشؽيخ اىؼَشٝخ  32
 ثغجت ٍشع اسرفبع ػغؾ  اىؼِٞ (عي٘مٍ٘ب)  
 5 4 3 2 1
ذ أّ ٍِ اىََنِ أُ أطبة ثَشع أخش ٝغجت اىؼَٚ غٞش اػزق 42
 ٍشع اسرفبع ػغؾ  اىؼِٞ (عي٘مٍ٘ب)  
 5 4 3 2 1
 5 4 3 2 1 ىغذ ثؾبعخ ئىٚ اخز قطشاد اىؼغؾ    52
 ٍؼٞقبد الاىزضاً ثبىؼلاط
أٛ ٍِ اىؼ٘اٍو اىزبىٞخ رؼٞق اىزضاٍل ثبعزخذاً اىقطشاد فٜ  
 اىؼلاط 
غٞش   غٞش ٍ٘افق ثشذح
 ٍ٘افق
 لا
 اػشف
ٍ٘افق  ٍ٘افق
 ثشذح
 5 4 3 2 1 أؽٞبّب  لا  أرزمش اعزخذاً قطشاد اىؼغؾ (عي٘مٍ٘ب) 62
 5 4 3 2 1 أؽٞبّب  أّبً  قجو ٍ٘ػذ اعزخذاً قطشاد اىؼغؾ (عي٘مٍ٘ب)  72
 5 4 3 2 1 أؽٞبّب اىقطشاد لا  رنُ٘ ٍؼٜ ػْذٍب ٝؾِٞ  ٗقذ اعزخذاٍٖب 82
 5 4 3 2 1 ٍشٝؾخ ىلاعزخذاً  أؽٞبّب اىقطشاد رنُ٘ ٍإىَخ ٗغٞش 92
 5 4 3 2 1 أعؼبس قطشاد اىؼغؾ (عي٘مٍ٘ب) ٍؼق٘ىخ 03
أػبّٜ ٍِ الأػشاع اىغبّجٞخ  ػْذ  اعزخذاً قطشاد اىؼغؾ  13
 (عي٘مٍ٘ب)
 5 4 3 2 1
 5 4 3 2 1 أؽٞبّب لا ر٘عذ ػْذٛ قطشاد اىؼغؾ (عي٘مٍ٘ب) 23
 5 4 3 2 1 قطشارٜ لا رغجت ىٜ  الأىٌ أٗ الاّضػبط 33
 5 4 3 2 1 ىذٛ طؼ٘ثخ  ثبعزخذاً  قطشاد اىؼِٞ 43
 5 4 3 2 1 اؽزبط  ٍغبػذح  ى٘ػغ اىقطشاد فٜ ػْٜٞٞ 53
 5 4 3 2 1 قطشارٜ  طؼجخ الاعزخذاً 63
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 5 4 3 2 1 اعزطٞغ  ٗػغ اىقطشح ثبىؼِٞ دُٗ أٝخ ٍغبػذح  73
اعزخذً قطشارٜ مو ىٞيخ لأّٖب ٍَٖخ ىيؾفبظ ػيٚ اىْظش ٗ ػجؾ  83
 غؾ اىؼِٞػ
 5 4 3 2 1
ْٕبك أشٞبء  اعزطٞغ اىقٞبً  ثٖب ىيغٞطشح ػيٚ ٍشع اسرفبع   93
 ػغؾ اىؼِٞ (عي٘مٍ٘ب)
 5 4 3 2 1
ْٕبك أشٞبء  اعزطٞغ اىقٞبً  ثٖب ىَْغ رذٕ٘س ٗػغ   اىؼِٞ ٗ  04
 اىْظش ىلأع٘أ ّزٞغخ ٍشع اسرفبع ػغؾ اىؼِٞ (عي٘مٍ٘ب)
 5 4 3 2 1
 ثؼذً الاىزضاً الاىزضاً ثبىؼلاط  ٗالاػزشاف
أٛ ٍِ ٕزٓ اىؼ٘اٍو اىخبطخ  شغؼزل ػيٚ الاىزضاً ثبعزخذاً  
 ).24-14قطشاد اىؼغؾ (اىؼجبساد ٍِ 
 )44-34اػزشاف اىَشٝغ ثبىزضاً (اىؼجبساد ٍِ 
غٞش   غٞش ٍ٘افق ثشذح
 ٍ٘افق
لا 
 اػشف
ٍ٘افق  ٍ٘افق
 ثشذح
 5 4 3 2 1 اعزخذً  ٍْجٔ  لإػلاٍٜ ػِ  ٗقذ  اىقطشاد  14
ىزغشثخ اىْبعؾخ لأؽذ أفشاد اىؼبئيخ أٗ الأطذقبء ٍغ اىقطشاد ا 24
ىيغٞطشح ػيٚ ٍشع اسرفبع ػغؾ اىؼِٞ (عي٘مٍ٘ب)  رشغؼْٜ 
 ػيٚ اعزخذاٍٖب  
 5 4 3 2 1
 5 4 3 2 1 ريزضً ثبعزخذاً قطشاد اىؼغؾ مو ًٝ٘  34
 5 4 3 2 1 اىشٖش اىَبػٜ   ىٌ  أَّظ أُ اعزخذً  أٛ ٍِ  قطشاد اىؼغؾ  44
 ٘اٍو اىَشرجطخ ثَضٗدٛ اىخذٍبد اىظؾٞخ ىؼا
ػلاقخ اىَشٝغ ثبىطجٞت اىَؼبىظ ئىٚ أٛ ٍذٙ ر٘افق ػيٚ ٕزٓ  
 اىؼجبساد 
غٞش   غٞش ٍ٘افق ثشذح
 ٍ٘افق
لا 
 اػشف
ٍ٘افق  ٍ٘افق
 ثشذح
أّب  ارفق رَبٍب ًٍغ رشخٞض ؽجٞجٜ ىٜ مَشٝغ ثبسرفبع ػغؾ  54
 اىؼِٞ (عي٘مٍ٘ب) 
 5 4 3 2 1
 5 4 3 2 1 ىٜ ؽجٞجٜ لا ٝغزَغ 64
أّب  عؼٞذ ثْ٘ػٞخ اىشػبٝخ اىطجٞخ  اىَقذٍخ ىٜ ٍِ ؽجٞجٜ(ٝششػ  74
ىٜ مو ٍب ٝزؼيق ثَشع اسرفبع ػغؾ اىؼِٞ(عي٘مٍ٘ب) ٗاىؼلاط 
 ٗمٞفٞخ الاعزخذاً اىظؾٞؼ ىيقطشاد)
 5 4 3 2 1
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Annex C: Questionnaire in English language. 
Glaucoma Treatment and Compliance Assessment Tool (GTCAT) 
 
Demographics information: 
1) Did participant need assistance reading the questionnaire?       1-Yes            2- No 
 
2)  Age: ___________ years 
 
3) Sex:                         1-Male            2-Female 
 
4) Marital Status:       1- Married    2-Single    3-Widowed    4-Divorced 
 
5)   Educational level:                1- Illiterate         2- Primary school       3-Secondary school             4- 
Diploma             5- PA degree              6- Master degree. 
6) Job /occupation:                      1- Employed /labor            2- Retired     3- House wife          
 4-Unemployed      5-Other specify……………………………… 
 
7) Household Income:                 1- up to 1500 NIS     2- 1500-2499 NIS      3- 2500-3499NIS 
                                             4- 3500-4499 NIS     5- 4500-5499 NIS      6- 5500 and more 
       
8) Address \ location :               1- City                 2- Rural area         3- Camp   
 
        9) Is there health insurance for the family                 1- Yes        2-  No 
 
                         10) If yes ,  what is the type of the insurance:         1- Public insurance     2- Private 
insurance                                          3- UNRWA insurance            4- other ………………………………   
            
    11) Does family insurance cover the cost of  glaucoma checkup and treatments? 
                                    1-High  percentage    2- Moderate percentage    3- Low percentage  
                                          4- Doesn‘t cover        5- I don‘t know 
    12) Date of first diagnosed: …………………years (duration of the disease). 
    13) What is the number of eye glaucoma medication (eye drops)  prescribed:  
        1-One                         2-Two                                     3-Three or more 
    14) Frequency of using eye drops:  
        1-Once a day              2-Two time a day                    3-Three times a day 
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    15) Surgical Procedures related to glaucoma  performed (past 3 month): 
            1-Yes                        2-No 
    16) Is there past family history with glaucoma? 
            1-Yes                        2-No 
    17) Do you have any systemic comorbidity such as hypertension ,diabetes, and ischemic heart   
disease?  
            1-Yes                        2-No 
 
    18) 
Two most recent intra-ocular 
pressure results 
Previous visit Current visit 
Right Eye   
Left Eye   
 
   19) Is transportation and access available between the place of residence and SJEHG which offers 
follow up for glaucoma patients? 
            1-Yes                        2-No 
   20)    
Visual acuity 
Category 
Normal Vision  
(6/12-6/6 ) 
Low Vision  
(LP - 6/18) 
Blindness (complete lack of light 
perception, "NLP," 
RT eye    
LT eye    
 
   
 21) Whose refer you to SJEHG ? 
1-Governmental Hospital 
2- Private Ophthalmic Clinic 
3-You came to check your vision, and you discover that you have glaucoma (self referral).  
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Below are several statements. Some are about glaucoma in general, and some are about 
your experience with glaucoma medications. Please read each statement and circle the 
number that best represents your opinion. 
 
 
Knowledge of  patient's  about glaucoma disease 
 What you know about glaucoma disease Strongly 
Disagree        
 
 Disagree        Don‘t Know       Agree        Strongly 
Agree  
1 My personal knowledge of  the risk factors for 
glaucoma is excellent    
1 2 3 4 5 
2  My personal knowledge of  the symptoms of 
glaucoma is excellent 
1 2 3 4 5 
3 Glaucoma is always genetic 1 2 3 4 5 
4 A person can have glaucoma and not know it. 1 2 3 4 5 
5 Being older increases the chances of developing 
glaucoma. 
1 2 3 4 5 
6 Eye pain is a common  symptom of glaucoma. 1 2 3 4 5 
7 Glaucoma can occur with normal eye pressure. 1 2 3 4 5 
8 Vision lost from glaucoma is permanent. 1 2 3 4 5 
9 Glaucoma can be caused by diabetes. 1 2 3 4 5 
10 Glaucoma can be caused by  an eye injury. 1 2 3 4 5 
11 Blindness is not a possible result of glaucoma. 1 2 3 4 5 
12 The reasons people get glaucoma are not well 
understood. 
1 2 3 4 5 
13 Major vision loss from glaucoma can be 
prevented with treatment. 
1 2 3 4 5 
14 I think I will go blind in 10  
years if I DO use my eye drops 
1 2 3 4 5 
15 Eye drop medication can totally control the 
negative progress of my glaucoma. 
1 2 3 4 5 
Awareness of glaucoma patient's to the severity of their  disease (glaucoma) 
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 What is the level of your agreement with these 
sentences 
Strongly 
Disagree        
 
 Disagree        Don‘t Know       Agree        Strongly 
Agree  
16 The level of my eye disease is not severe. 1 2 3 4 5 
17 I have lost none of my vision due to glaucoma. 1 2 3 4 5 
18 All of my vision could be lost due to glaucoma 1 2 3 4 5 
19 If I lost the same amount of  vision over the next 
five years as I have over the past five, it would 
have no effect on my quality of life. 
1 2 3 4 5 
20 I think I will go blind in 5 years if I DO NOT use 
my eye drops. 
1 2 3 4 5 
21 I think I will go blind in 10 years if I DO NOT 
use my eye drops 
1 2 3 4 5 
22 I was not surprised to have gotten glaucoma. 1 2 3 4 5 
23 I am more susceptible to  blindness than other 
people my age. 
1 2 3 4 5 
24 I think I will develop other  potentially blinding 
eye diseases. 
1 2 3 4 5 
25 I don‘t need to take drops. 1 2 3 4 5 
Barrier to compliance with treatment 
 Which one of these barriers considered a barrier 
for you to compliance with topical anti-
glaucoma treatment 
Strongly 
Disagree        
 
 Disagree        Don‘t 
Know       
Agree        Strongly 
Agree  
26 Sometimes I forget to use my drops. 1 2 3 4 5 
27 Sometimes I fall asleep before dosing time 1 2 3 4 5 
28 Sometimes the drops aren‘t with me when it is 
time to take them. 
1 2 3 4 5 
29 Sometimes the drops are painful or 
uncomfortable to take. 
1 2 3 4 5 
30 My eye drops are  reasonably priced 1 2 3 4 5 
31 I suffer from side effects when using my drops. 1 2 3 4 5 
32 Sometimes I am out of drops. 1 2 3 4 5 
33 My eye drops cause me no  pain or discomfort. 1 2 3 4 5 
34 I have a great deal of difficulty putting in my 1 2 3 4 5 
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eye drops. 
35 I need assistance putting  drops in my eyes. 1 2 3 4 5 
36 My eye drops are difficult  to use. 1 2 3 4 5 
37 I can place the eye drops into my eye correctly 
without any assistance. 
1 2 3 4 5 
38 I will always use my eye drops every night. 1 2 3 4 5 
39 There are things I can do to control my 
glaucoma. 
1 2 3 4 5 
40 There are things I can do to prevent my 
glaucoma from getting worse. 
1 2 3 4 5 
Cause to action questions and Self reported compliance  
 What encourage you to compliance with topical 
anti-glaucoma treatment(statement from41-43) 
Self reported compliance (statement 44-45) 
Strongly 
Disagree        
 
Disagree        Don‘t 
Know       
Agree        Strongly 
Agree  
41 I use reminders to help me remember to take my 
eye drop medications. 
1 2 3 4 5 
42 A friend or family member‘s experience with 
eye drops has encouraged me to use my eye 
drops 
1 2 3 4 5 
43 Are you use your eye drops daily  1 2 3 4 5 
44 Over the last month I have not missed taking my 
eye drops 
1 2 3 4 5 
Patient –physician relationship  
 Related to patient-physician relationship   Strongly 
Disagree        
 
Disagree        Don‘t 
Know       
Agree        Strongly 
Agree 
45 I completely agree with my  doctor‘s diagnosis 
of glaucoma in my eye(s). 
1 2 3 4 5 
46 My doctor does not listen to  me. 1 2 3 4 5 
47 I am happy with the care I  get from my eye 
doctor(explain every things about the disease, 
it's treatments ,and the best way to use eye 
drops) 
1 2 3 4 5 
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Set of  Questionnaire Axis:  
Knowledge: Statements1, 2, 3, 4,5, 6, 7, 8, 9, 10,11, 12 
Benefits: Statements 13,14,15 
Severity: Statements 16,17,18,19 
Susceptibility: Statements 20,21,22,23,24,25 
Barriers to compliance with treatment:26,27,28,29,30,31,32,33    
Self-efficacy: Statements 34,35,36,37,38,39,40 
Cues-to-action: Statements 41,42 
Self-report adherence: Statement 44,45 
Patient-physician relationship: Statements 45,46,47 
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Annex D: Cronbach's Alpha test for reliability and validity of the 
study tool. 
 
Reliability : 
For test the reliability of the questionnaire Chronbach Alpha calculated where it 0.733 
which mean the questionnaire has a good level of reliability as in the table. 
 
 Chronbach alpha Number of items Sample size 
Knowledge 0.512 15 17 
Awareness of glaucoma 0.936 10 17 
Barriers 0.319 15 17 
Cause to action 0.768 4 17 
Physician relationship 0.633 3 17 
Total degree 0.733 47 17 
 
Validity:  
The total degree is divided into two part more than three and less than three then use 
independent samples T–test if the questionnaire can discriminate between the two 
groups.  
 
The tool can discriminate between the noncompliance and compliance groups.   
 
 
 
 
 
Sig. Df T St.dv Mean   
.000 15 -4.697 .19558 2.7979 Noncompliance Total 
degree 
.12463 3.2596 Compliance 
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العوامل المؤثرة في التزام مرضى ضغط العين (جموكوما) باستخدام القطرات في مستشفى 
 سان جون لمعيون (القدس والخميل وعنبتا).
 الحسنات حسين : ختام ابراهيم اعداد الطالبة
 اسم المشرف : د. محمد شاهين
 ممخص ال
الجموكوما ىي السبب الرئيسي الثاني لمعمى في العالم. أحد العوامل ذات الصمة  المقدمة :
ضغط المساىمة في ىذه المشكمة ىو عدم الالتزام باستخدام العلاج بالقطرات المضادة لارتفاع 
٪ من قبل  8:العين "القطرات"  بنسبة . تستخدم الأدوية الخافضة لضغط العين (جموكوما)
ويعتبر ىذا العلاج الأكثر شيوعا. عمى الرغم من أن  جموكوما،الالمرضى الذين يعانون مرض 
التشخيص الصحيح ىو جزء أساسي في علاج ىذا المرض ، إلا ان العلاج المناسب لو عمى قدم 
يحتاجون لمعلاج  رض الجموكوماالمساواة ، إن لم يكن أكبر أىمية. المرضى الذين يعانون من م
٪ 2:٪ لتصل الى 7مدى الحياة والمتابعة لمحفاظ عمى النظر. نسبة الالتزام في العالم  تتراوح من 
وبالنسبة ليذا الموضوع تتوفر معمومات محدودة في الشرق الأوسط . بينما  في فمسطين لا يوجد 
 ات في ىذا المجال. بسبب عدم وجود دراسجموكوما المعمومات متوفرة حول مرضى 
 
اليدف من ىذه الدراسة ىو تقييم مستوى الالتزام والعوامل التي تؤثر عمى الالتزام  الهدف :
باستخدام القطرات من قبل مرضى الجموكوما في مستشفى سان جون لمعيون في (القدس والخميل 
 وعنبتا) .
 
يارىم بشكل عشوائي من عيادات المشاركين في ىذه الدراسة الوصفية المقطعيو تم اخت الطريقة :
.  وكانت 365الجموكوما في مستشفى سان جون لمعيون في القدس والخميل وعنبتا  وكان عددىن 
)، حيث استخدمت لتقييم الالتزام بالعلاج باستخدام TACTGالأداة الرئيسية لمبحث الاستبانة (
اعتمد الاستبيان عمى نموذج  القطرات والعوامل التي تؤثر عميو  من قبل مرضى الجموكوما. وقد
المعتقدات بجوانبو الستة ، فضلا عن المعمومات الأخرى ذات الصمة مثل العمر والتاريخ الطبي 
 7والجنس والدخل ومستويات التعميم ونوع  التغطية التأمينية. وتشمل معظم الأسئمة ردا من  
 < موافق بشده).7< لا اوافق بشده،.....3اجابات مقياس ليكرت (عمى سبيل المثال 
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تم تعبئة الاستبانة من خلال لقاء شخصي مع مرضى الجموكوما من قبل اشخاص متدربين و 
محايدين. استخدمت الاختبارات التالية في تحميل العينة (الإحصاء الوصفي والتكرارات، اختباركاي 
 ، تم تطبيق اختبار الانحدار).AVONA، اختبار 
 
٪) 69٪) ، عدم الالتزام لدى الذكور أكثر من الإناث (8.39تزام (كان مستوى عدم الال النتائج :
٪) عمى التوالي. عدم الالتزام يزداد  مع التقدم في السن حيث أن مستوى عدم الالتزام ;8إلى (
 سنة . 2: - 27مرتفع من عمر  
اطمين ٪). المتقاعدين والع6;كان أعمى مستوى من عدم الالتزام لدى مرضى الجموكوما المطمقين (
٪). و كان مستوى عدم الالتزام ;9٪) و (3:عن العمل لدييم مستوى عالي من عدم الالتزام (
 ٪)  لدى مرضى الجموكوما الذين يتم اعتبارىم  كفيفين فيما يتعمق بحدة البصر. ;9عاليا (
المستوى التعميمي ادى الى تحسين مستوى الالتزام حيث كان أعمى مستوى من عدم الالتزام لدى 
٪). المشاركين في الدراسة  كان لدييم مستوى معتدل من المعرفة حول مرض 89الأميين (
الجموكوما والتي كانت عاملا ىاما مؤثرا عمى الالتزام بشكل إيجابي وكذلك بالنسبة لمكفاءة الذاتيو 
 لممرضى.
لتزام كانت اولا< درجة  الا معيقات العلاج ليا تأثير سمبي عمى الالتزام. العوامل الأكثر تأثيرا عمى
د  القطرات مع مرضى الجموكوما عندما يحين الوقت لاستخداميا ، ثانيا< الآثار الجانبية و جعدم و 
 عند استخدام القطرات ، ثالثا< النسيان.
وعمى الرغم من أن غالبية مرضى الجموكوما المشاركين لدييم تأمين صحي كان لدييم مستوى عال 
 حصموا عمى تغطية تكاليف المتابعة والعلاج من التأمين.من عدم الالتزام لأنيم لم ي
 
 
 الكممات المفتاحيو<
 الجموكوما، الامتثال، الالتزام، ادوية الجموكوما (قطرات المضادة لمجموكوما)
 
 
